<!DOCTYPE html>
<html lang="en" dir="ltr" class="client-nojs">
<head>
<meta charset="UTF-8" />
<title>Acute myeloid leukemia - Wikipedia, the free encyclopedia</title>
<meta name="generator" content="MediaWiki 1.26wmf13" />
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Acute_myeloid_leukemia" />
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit" />
<link rel="edit" title="Edit this page" href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit" />
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png" />
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico" />
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd" />
<link rel="alternate" hreflang="x-default" href="/wiki/Acute_myeloid_leukemia" />
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/" />
<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
<link rel="canonical" href="https://en.wikipedia.org/wiki/Acute_myeloid_leukemia" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.uls.nojs%7Cext.visualEditor.viewPageTarget.noscript%7Cext.wikihiero%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.sectionAnchor%7Cmediawiki.skinning.interface%7Cmediawiki.ui.button%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector&amp;*" />
<meta name="ResourceLoaderDynamicStyles" content="" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=styles&amp;skin=vector&amp;*" />
<style>a:lang(ar),a:lang(kk-arab),a:lang(mzn),a:lang(ps),a:lang(ur){text-decoration:none}
/* cache key: global:resourceloader:filter:minify-css:7:de1ab5287c9076b96eedd3f97a84a7b6 */</style>
<script src="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector&amp;*"></script>
<script>if(window.mw){
mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Acute_myeloid_leukemia","wgTitle":"Acute myeloid leukemia","wgCurRevisionId":666154792,"wgRevisionId":666154792,"wgArticleId":4323952,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["CS1 German-language sources (de)","Use dmy dates from March 2014","Articles with contributors link","Articles with DMOZ links","Articles that use a Medicine navs subtemplate","Featured articles","Acute myeloid leukemia"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Acute_myeloid_leukemia","wgRelevantArticleId":4323952,"wgIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgRedirectedFrom":"Acute_myeloblastic_leukemia_type_2","wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wikilove-recipient":"","wikilove-anon":0,"wgPoweredByHHVM":true,"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"hidesig":true,"preview":false,"publish":false},"wgBetaFeaturesFeatures":[],"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","usePageImages":true,"usePageDescriptions":true},"wgGatherShouldShowTutorial":true,"wgGatherPageImageThumbnail":"//upload.wikimedia.org/wikipedia/commons/thumb/d/d8/Auer_rods.PNG/100px-Auer_rods.PNG","wgULSAcceptLanguageList":[],"wgULSCurrentAutonym":"English","wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgNoticeProject":"wikipedia","wgInternalRedirectTargetUrl":"/wiki/Acute_myeloid_leukemia","wgWikibaseItemId":"Q264118"});
}</script><script>if(window.mw){
mw.loader.implement("user.options",function($,jQuery){mw.user.options.set({"variant":"en"});});
/* cache key: global:resourceloader:filter:minify-js:7:b2706269305541eba923c165462b22c4 */
}</script>
<script>if(window.mw){
mw.loader.implement("user.tokens",function($,jQuery){mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\"});});
}</script>
<script>if(window.mw){
mw.loader.load(["mediawiki.action.view.redirect","mediawiki.page.startup","mediawiki.legacy.wikibits","mediawiki.legacy.ajax","ext.centralauth.centralautologin","mmv.head","ext.imageMetrics.head","ext.visualEditor.viewPageTarget.init","ext.uls.init","ext.uls.interface","ext.centralNotice.bannerController","skins.vector.js"]);
}</script>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 7]><style type="text/css">body{behavior:url("/w/static/1.26wmf13/skins/Vector/csshover.min.htc")}</style><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Acute_myeloid_leukemia skin-vector action-view">
		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>

							<div id="siteNotice"><!-- CentralNotice --></div>
						<div class="mw-indicators">
<div id="mw-indicator-featured-star" class="mw-indicator"><a href="/wiki/Wikipedia:Featured_articles" title="This is a featured article. Click here for more information."><img alt="This is a featured article. Click here for more information." src="//upload.wikimedia.org/wikipedia/en/thumb/e/e7/Cscr-featured.svg/20px-Cscr-featured.svg.png" width="20" height="19" srcset="//upload.wikimedia.org/wikipedia/en/thumb/e/e7/Cscr-featured.svg/30px-Cscr-featured.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/e/e7/Cscr-featured.svg/40px-Cscr-featured.svg.png 2x" data-file-width="462" data-file-height="438" /></a></div>
</div>
			<h1 id="firstHeading" class="firstHeading" lang="en">Acute myeloid leukemia</h1>
									<div id="bodyContent" class="mw-body-content">
									<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"><span class="mw-redirectedfrom">  (Redirected from <a href="/w/index.php?title=Acute_myeloblastic_leukemia_type_2&amp;redirect=no" title="Acute myeloblastic leukemia type 2">Acute myeloblastic leukemia type 2</a>)</span></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-head">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><table class="infobox" style="width:22em">
<tr>
<th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;background-color: lightgrey">Acute myeloid leukemia</th>
</tr>
<tr>
<td colspan="2" style="text-align:center"><a href="/wiki/File:Auer_rods.PNG" class="image"><img alt="Auer rods.PNG" src="//upload.wikimedia.org/wikipedia/commons/thumb/d/d8/Auer_rods.PNG/230px-Auer_rods.PNG" width="230" height="214" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/d/d8/Auer_rods.PNG/345px-Auer_rods.PNG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d8/Auer_rods.PNG/460px-Auer_rods.PNG 2x" data-file-width="1548" data-file-height="1440" /></a>
<div>Bone marrow aspirate showing acute myeloid leukemia. Arrows indicate <a href="/wiki/Auer_rods" title="Auer rods" class="mw-redirect">Auer rods</a>.</div>
</td>
</tr>
<tr>
<th colspan="2" style="text-align:center">Classification and external resources</th>
</tr>
<tr>
<th scope="row"><a href="/wiki/Specialty_(medicine)" title="Specialty (medicine)">Specialty</a></th>
<td><a href="/wiki/Hematology" title="Hematology">Hematology</a> and <a href="/wiki/Oncology" title="Oncology">oncology</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/ICD-10" title="ICD-10">10</a></th>
<td><a rel="nofollow" class="external text" href="http://apps.who.int/classifications/icd10/browse/2015/en#/C92.0">C92.0</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/List_of_ICD-9_codes" title="List of ICD-9 codes">9-CM</a></th>
<td><a rel="nofollow" class="external text" href="http://www.icd9data.com/getICD9Code.ashx?icd9=205.0">205.0</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Classification_of_Diseases_for_Oncology" title="International Classification of Diseases for Oncology">ICD-O</a></th>
<td><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">M</a><a rel="nofollow" class="external text" href="http://www.progenetix.net/progenetix/I98613/">9861/3</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/OMIM" title="OMIM" class="mw-redirect">OMIM</a></th>
<td><a rel="nofollow" class="external text" href="http://omim.org/entry/602439">602439</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Diseases_Database" title="Diseases Database">DiseasesDB</a></th>
<td><a rel="nofollow" class="external text" href="http://www.diseasesdatabase.com/ddb203.htm">203</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th>
<td><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/medlineplus/ency/article/000542.htm">000542</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></th>
<td><a rel="nofollow" class="external text" href="http://www.emedicine.com/med/topic34.htm">med/34</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/National_Cancer_Institute" title="National Cancer Institute">NCI</a></th>
<td><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancertopics/types/leukemia">Acute myeloid leukemia</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Patient_UK" title="Patient UK">Patient UK</a></th>
<td><a rel="nofollow" class="external text" href="http://patient.info/doctor/acute-myeloid-leukaemia-pro">Acute myeloid leukemia</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Medical_Subject_Headings" title="Medical Subject Headings">MeSH</a></th>
<td><a rel="nofollow" class="external text" href="//www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&amp;term=D015470">D015470</a></td>
</tr>
</table>
<p><b>Acute myeloid leukemia</b> (<b>AML</b>), also known as <b>acute myelogenous leukemia</b> or <b>acute nonlymphocytic leukemia</b> (<b>ANLL</b>), is a <a href="/wiki/Cancer" title="Cancer">cancer</a> of the <a href="/wiki/Myeloid" title="Myeloid">myeloid</a> line of blood cells, characterized by the rapid growth of abnormal <a href="/wiki/White_blood_cell" title="White blood cell">white blood cells</a> that accumulate in the <a href="/wiki/Bone_marrow" title="Bone marrow">bone marrow</a> and interfere with <a href="/wiki/Haematopoiesis" title="Haematopoiesis">the production of normal blood cells</a>. AML is the most common <a href="/wiki/Acute_leukemia" title="Acute leukemia">acute leukemia</a> affecting adults, and its <a href="/wiki/Incidence_(epidemiology)" title="Incidence (epidemiology)">incidence</a> increases with age. Although AML is a relatively <a href="/wiki/Rare_disease" title="Rare disease">rare disease</a>, accounting for approximately 1.2% of cancer deaths in the United States,<sup id="cite_ref-cancerstats_1-0" class="reference"><a href="#cite_note-cancerstats-1"><span>[</span>1<span>]</span></a></sup> its incidence is expected to increase as the population ages.</p>
<p>The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in <a href="/wiki/Red_blood_cell" title="Red blood cell">red blood cells</a>, <a href="/wiki/Platelet" title="Platelet">platelets</a>, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several <a href="/wiki/Risk_factors" title="Risk factors" class="mw-redirect">risk factors</a> and <a href="/wiki/Chromosome_abnormality" title="Chromosome abnormality">chromosomal abnormalities</a> have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.</p>
<p>AML has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33–78%, depending on subtype. AML is treated initially with <a href="/wiki/Chemotherapy" title="Chemotherapy">chemotherapy</a> aimed at inducing a <a href="/wiki/Remission_(medicine)" title="Remission (medicine)" class="mw-redirect">remission</a>; patients may go on to receive additional chemotherapy or a <a href="/wiki/Hematopoietic_stem_cell_transplant" title="Hematopoietic stem cell transplant" class="mw-redirect">hematopoietic stem cell transplant</a>. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.</p>
<div class="toclimit-3">
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Signs_and_symptoms"><span class="tocnumber">1</span> <span class="toctext">Signs and symptoms</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Causes"><span class="tocnumber">2</span> <span class="toctext">Causes</span></a>
<ul>
<li class="toclevel-2 tocsection-3"><a href="#Preleukemia"><span class="tocnumber">2.1</span> <span class="toctext">Preleukemia</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Chemical_exposure"><span class="tocnumber">2.2</span> <span class="toctext">Chemical exposure</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Radiation"><span class="tocnumber">2.3</span> <span class="toctext">Radiation</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Genetics"><span class="tocnumber">2.4</span> <span class="toctext">Genetics</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-7"><a href="#Diagnosis"><span class="tocnumber">3</span> <span class="toctext">Diagnosis</span></a>
<ul>
<li class="toclevel-2 tocsection-8"><a href="#World_Health_Organization"><span class="tocnumber">3.1</span> <span class="toctext">World Health Organization</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#French-American-British"><span class="tocnumber">3.2</span> <span class="toctext">French-American-British</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-10"><a href="#Pathophysiology"><span class="tocnumber">4</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-1 tocsection-11"><a href="#Treatment"><span class="tocnumber">5</span> <span class="toctext">Treatment</span></a>
<ul>
<li class="toclevel-2 tocsection-12"><a href="#Induction"><span class="tocnumber">5.1</span> <span class="toctext">Induction</span></a></li>
<li class="toclevel-2 tocsection-13"><a href="#Consolidation"><span class="tocnumber">5.2</span> <span class="toctext">Consolidation</span></a></li>
<li class="toclevel-2 tocsection-14"><a href="#Relapsed_AML"><span class="tocnumber">5.3</span> <span class="toctext">Relapsed AML</span></a>
<ul>
<li class="toclevel-3 tocsection-15"><a href="#Clinical_trials"><span class="tocnumber">5.3.1</span> <span class="toctext">Clinical trials</span></a></li>
<li class="toclevel-3 tocsection-16"><a href="#Relapsed_APL"><span class="tocnumber">5.3.2</span> <span class="toctext">Relapsed APL</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-17"><a href="#Prognosis"><span class="tocnumber">6</span> <span class="toctext">Prognosis</span></a>
<ul>
<li class="toclevel-2 tocsection-18"><a href="#Cytogenetics"><span class="tocnumber">6.1</span> <span class="toctext">Cytogenetics</span></a></li>
<li class="toclevel-2 tocsection-19"><a href="#Myelodysplastic_syndrome"><span class="tocnumber">6.2</span> <span class="toctext">Myelodysplastic syndrome</span></a></li>
<li class="toclevel-2 tocsection-20"><a href="#Other_prognostic_markers"><span class="tocnumber">6.3</span> <span class="toctext">Other prognostic markers</span></a>
<ul>
<li class="toclevel-3 tocsection-21"><a href="#Genotype"><span class="tocnumber">6.3.1</span> <span class="toctext">Genotype</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-22"><a href="#Expectation_of_cure"><span class="tocnumber">6.4</span> <span class="toctext">Expectation of cure</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-23"><a href="#Epidemiology"><span class="tocnumber">7</span> <span class="toctext">Epidemiology</span></a>
<ul>
<li class="toclevel-2 tocsection-24"><a href="#UK"><span class="tocnumber">7.1</span> <span class="toctext">UK</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-25"><a href="#History"><span class="tocnumber">8</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1 tocsection-26"><a href="#Pregnancy"><span class="tocnumber">9</span> <span class="toctext">Pregnancy</span></a></li>
<li class="toclevel-1 tocsection-27"><a href="#References"><span class="tocnumber">10</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-28"><a href="#External_links"><span class="tocnumber">11</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
</div>
<h2><span class="mw-headline" id="Signs_and_symptoms">Signs and symptoms</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=1" title="Edit section: Signs and symptoms">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:AMLCase-66.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/d/d0/AMLCase-66.jpg/220px-AMLCase-66.jpg" width="220" height="159" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/d/d0/AMLCase-66.jpg/330px-AMLCase-66.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d0/AMLCase-66.jpg/440px-AMLCase-66.jpg 2x" data-file-width="970" data-file-height="702" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:AMLCase-66.jpg" class="internal" title="Enlarge"></a></div>
Diffusely swollen gums due to infiltration by leukemic cells in a person with acute myelomonocytic leukemia</div>
</div>
</div>
<p>Most signs and symptoms of AML are caused by the replacement of normal blood cells with leukemic cells. A lack of normal white blood cell production makes the patient susceptible to infections; while the leukemic cells themselves are derived from white blood cell precursors, they have no infection-fighting capacity.<sup id="cite_ref-symptoms_2-0" class="reference"><a href="#cite_note-symptoms-2"><span>[</span>2<span>]</span></a></sup> A drop in red blood cell count (<a href="/wiki/Anemia" title="Anemia">anemia</a>) can cause fatigue, paleness, and shortness of breath. A lack of <a href="/wiki/Platelet" title="Platelet">platelets</a> can lead to easy bruising or bleeding with minor trauma.</p>
<p>The early signs of AML are often vague and nonspecific, and may be similar to those of <a href="/wiki/Influenza" title="Influenza">influenza</a> or other common illnesses. Some generalized symptoms include <a href="/wiki/Fever" title="Fever">fever</a>, <a href="/wiki/Fatigue_(physical)" title="Fatigue (physical)" class="mw-redirect">fatigue</a>, <a href="/wiki/Weight_loss" title="Weight loss">weight loss</a> or <a href="/wiki/Loss_of_appetite" title="Loss of appetite" class="mw-redirect">loss of appetite</a>, <a href="/wiki/Dyspnea" title="Dyspnea">shortness of breath</a>, anemia, easy bruising or bleeding, <a href="/wiki/Petechia" title="Petechia">petechiae</a> (flat, pin-head sized spots under the skin caused by bleeding), bone and joint pain, and persistent or frequent <a href="/wiki/Infections" title="Infections" class="mw-redirect">infections</a>.<sup id="cite_ref-symptoms_2-1" class="reference"><a href="#cite_note-symptoms-2"><span>[</span>2<span>]</span></a></sup></p>
<p><a href="/wiki/Splenomegaly" title="Splenomegaly">Enlargement of the spleen</a> may occur in AML, but it is typically mild and <a href="/wiki/Asymptomatic" title="Asymptomatic">asymptomatic</a>. <a href="/wiki/Lymphadenopathy" title="Lymphadenopathy">Lymph node swelling</a> is rare in AML, in contrast to <a href="/wiki/Acute_lymphoblastic_leukemia" title="Acute lymphoblastic leukemia">acute lymphoblastic leukemia</a>. The skin is involved about 10% of the time in the form of <a href="/wiki/Chloroma" title="Chloroma" class="mw-redirect">leukemia cutis</a>. Rarely, <a href="/wiki/Sweet%27s_syndrome" title="Sweet's syndrome" class="mw-redirect">Sweet's syndrome</a>, a <a href="/wiki/Paraneoplastic_syndrome" title="Paraneoplastic syndrome">paraneoplastic</a> inflammation of the skin, can occur with AML.<sup id="cite_ref-symptoms_2-2" class="reference"><a href="#cite_note-symptoms-2"><span>[</span>2<span>]</span></a></sup></p>
<p>Some patients with AML may experience swelling of the gums because of infiltration of leukemic cells into the gum tissue. Rarely, the first sign of leukemia may be the development of a solid leukemic mass or tumor outside of the <a href="/wiki/Bone_marrow" title="Bone marrow">bone marrow</a>, called a <a href="/wiki/Chloroma" title="Chloroma" class="mw-redirect">chloroma</a>. Occasionally, a person may show <a href="/wiki/Asymptomatic" title="Asymptomatic">no symptoms</a>, and the leukemia may be discovered incidentally during a routine <a href="/wiki/Blood_test" title="Blood test">blood test</a>.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3"><span>[</span>3<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Causes">Causes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=2" title="Edit section: Causes">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>A number of risk factors for developing AML have been identified, including: other blood disorders, chemical exposures, ionizing radiation, and genetics.</p>
<h3><span class="mw-headline" id="Preleukemia">Preleukemia</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=3" title="Edit section: Preleukemia">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>"Preleukemic" blood disorders, such as <a href="/wiki/Myelodysplastic_syndrome" title="Myelodysplastic syndrome">myelodysplastic syndrome</a> or <a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">myeloproliferative disease</a>, can evolve into AML; the exact risk depends on the type of MDS/MPS.<sup id="cite_ref-4" class="reference"><a href="#cite_note-4"><span>[</span>4<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Chemical_exposure">Chemical exposure</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=4" title="Edit section: Chemical exposure">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Exposure to <a href="/wiki/Chemotherapy" title="Chemotherapy">anticancer chemotherapy</a>, in particular <a href="/wiki/Alkylating_antineoplastic_agent" title="Alkylating antineoplastic agent">alkylating agents</a>, can increase the risk of subsequently developing AML. The risk is highest about three to five years after chemotherapy.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5"><span>[</span>5<span>]</span></a></sup> Other chemotherapy agents, specifically <a href="/wiki/Podophyllotoxin" title="Podophyllotoxin">epipodophyllotoxins</a> and <a href="/wiki/Anthracycline" title="Anthracycline">anthracyclines</a>, have also been associated with treatment-related leukemia. These treatment-related leukemias are often associated with specific chromosomal abnormalities in the leukemic cells.<sup id="cite_ref-6" class="reference"><a href="#cite_note-6"><span>[</span>6<span>]</span></a></sup></p>
<p>Occupational chemical exposure to <a href="/wiki/Benzene" title="Benzene">benzene</a> and other aromatic organic <a href="/wiki/Solvent" title="Solvent">solvents</a> is controversial as a cause of AML. Benzene and many of its derivatives are known to be <a href="/wiki/Carcinogenic" title="Carcinogenic" class="mw-redirect">carcinogenic</a> <i>in vitro</i>. While some studies have suggested a link between occupational exposure to benzene and increased risk of AML,<sup id="cite_ref-7" class="reference"><a href="#cite_note-7"><span>[</span>7<span>]</span></a></sup> others have suggested the attributable risk, if any, is slight.<sup id="cite_ref-8" class="reference"><a href="#cite_note-8"><span>[</span>8<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Radiation">Radiation</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=5" title="Edit section: Radiation">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>High amounts of <a href="/wiki/Ionizing_radiation" title="Ionizing radiation">ionizing radiation</a> exposure can increase the risk of AML. <a href="/wiki/Hibakusha" title="Hibakusha">Survivors of the atomic bombings of Hiroshima and Nagasaki</a> had an increased rate of AML,<sup id="cite_ref-9" class="reference"><a href="#cite_note-9"><span>[</span>9<span>]</span></a></sup> as did <a href="/wiki/Radiologist" title="Radiologist" class="mw-redirect">radiologists</a> exposed to high levels of <a href="/wiki/X-ray" title="X-ray">X-rays</a> prior to the adoption of modern radiation safety practices.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10"><span>[</span>10<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Genetics">Genetics</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=6" title="Edit section: Genetics">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>A hereditary risk for AML appears to exist. Multiple cases of AML developing in a family at a rate higher than predicted by chance alone have been reported.<sup id="cite_ref-11" class="reference"><a href="#cite_note-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-12" class="reference"><a href="#cite_note-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-13" class="reference"><a href="#cite_note-13"><span>[</span>13<span>]</span></a></sup><sup id="cite_ref-14" class="reference"><a href="#cite_note-14"><span>[</span>14<span>]</span></a></sup> Several <a href="/wiki/Congenital" title="Congenital" class="mw-redirect">congenital</a> conditions may increase the risk of leukemia; the most common is probably <a href="/wiki/Down_syndrome" title="Down syndrome">Down syndrome</a>, which is associated with a 10- to 18-fold increase in the risk of AML.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15"><span>[</span>15<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Diagnosis">Diagnosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=7" title="Edit section: Diagnosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Myeloblast_with_Auer_rod_smear_2010-01-27.JPG" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/f/f1/Myeloblast_with_Auer_rod_smear_2010-01-27.JPG/220px-Myeloblast_with_Auer_rod_smear_2010-01-27.JPG" width="220" height="165" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/f1/Myeloblast_with_Auer_rod_smear_2010-01-27.JPG/330px-Myeloblast_with_Auer_rod_smear_2010-01-27.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/f1/Myeloblast_with_Auer_rod_smear_2010-01-27.JPG/440px-Myeloblast_with_Auer_rod_smear_2010-01-27.JPG 2x" data-file-width="1446" data-file-height="1085" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Myeloblast_with_Auer_rod_smear_2010-01-27.JPG" class="internal" title="Enlarge"></a></div>
Bone marrow: myeloblasts with Auer rods seen in acute myeloid leukemia</div>
</div>
</div>
<p>The first clue to a diagnosis of AML is typically an abnormal result on a <a href="/wiki/Complete_blood_count" title="Complete blood count">complete blood count</a>. While an excess of abnormal white blood cells (<a href="/wiki/Leukocytosis" title="Leukocytosis">leukocytosis</a>) is a common finding, and leukemic blasts are sometimes seen, AML can also present with isolated decreases in <a href="/wiki/Platelet" title="Platelet">platelets</a>, <a href="/wiki/Red_blood_cell" title="Red blood cell">red blood cells</a>, or even with a <i>low</i> white blood cell count (<a href="/wiki/Leukopenia" title="Leukopenia">leukopenia</a>).<sup id="cite_ref-16" class="reference"><a href="#cite_note-16"><span>[</span>16<span>]</span></a></sup> While a presumptive diagnosis of AML can be made via examination of the <a href="/wiki/Blood_film" title="Blood film">peripheral blood smear</a> when there are circulating leukemic blasts, a definitive diagnosis usually requires an adequate <a href="/wiki/Bone_marrow_examination" title="Bone marrow examination">bone marrow aspiration and biopsy</a>.</p>
<p>Marrow or blood is examined via <a href="/wiki/Light_microscopy" title="Light microscopy" class="mw-redirect">light microscopy</a>, as well as <a href="/wiki/Flow_cytometry" title="Flow cytometry">flow cytometry</a>, to diagnose the presence of leukemia, to differentiate AML from other types of leukemia (e.g. <a href="/wiki/Acute_lymphoblastic_leukemia" title="Acute lymphoblastic leukemia">acute lymphoblastic leukemia</a> - ALL), and to classify the subtype of disease (see below). A sample of marrow or blood is typically also tested for <a href="/wiki/Chromosome_abnormality" title="Chromosome abnormality">chromosomal abnormalities</a> by routine <a href="/wiki/Cytogenetics" title="Cytogenetics">cytogenetics</a> or <a href="/wiki/Fluorescent_in_situ_hybridization" title="Fluorescent in situ hybridization" class="mw-redirect">fluorescent <i>in situ</i> hybridization</a>. Genetic studies may also be performed to look for specific mutations in genes such as <a href="/wiki/FLT3" title="FLT3" class="mw-redirect">FLT3</a>, <a href="/wiki/Nucleophosmin" title="Nucleophosmin" class="mw-redirect">nucleophosmin</a>, and <a href="/wiki/CD117" title="CD117">KIT</a>, which may influence the outcome of the disease.<sup id="cite_ref-17" class="reference"><a href="#cite_note-17"><span>[</span>17<span>]</span></a></sup></p>
<p>Cytochemical stains on blood and bone marrow smears are helpful in the distinction of AML from ALL, and in subclassification of AML. The combination of a myeloperoxidase or Sudan black stain and a nonspecific esterase stain will provide the desired information in most cases. The myeloperoxidase or Sudan black reactions are most useful in establishing the identity of AML and distinguishing it from ALL. The nonspecific esterase stain is used to identify a monocytic component in AMLs and to distinguish a poorly differentiated monoblastic leukemia from ALL.<sup id="cite_ref-Vardiman_18-0" class="reference"><a href="#cite_note-Vardiman-18"><span>[</span>18<span>]</span></a></sup></p>
<p>The diagnosis and classification of AML can be challenging, and should be performed by a qualified <a href="/wiki/Hematopathologist" title="Hematopathologist" class="mw-redirect">hematopathologist</a> or <a href="/wiki/Hematologist" title="Hematologist" class="mw-redirect">hematologist</a>. In straightforward cases, the presence of certain morphologic features (such as <a href="/wiki/Auer_rods" title="Auer rods" class="mw-redirect">Auer rods</a>) or specific flow cytometry results can distinguish AML from other leukemias; however, in the absence of such features, diagnosis may be more difficult.<sup id="cite_ref-19" class="reference"><a href="#cite_note-19"><span>[</span>19<span>]</span></a></sup></p>
<p>According to the widely used <a href="/wiki/WHO" title="WHO" class="mw-redirect">WHO</a> criteria, the diagnosis of AML is established by demonstrating involvement of more than 20% of the blood and/or bone marrow by leukemic <a href="/wiki/Myeloblast" title="Myeloblast">myeloblasts</a>.<sup id="cite_ref-20" class="reference"><a href="#cite_note-20"><span>[</span>20<span>]</span></a></sup> The French–American–British (FAB) classification is a bit more stringent, requiring a blast percentage of at least 30% in bone marrow (BM) or peripheral blood (PB) for the diagnosis of AML.<sup id="cite_ref-Amin2005_21-0" class="reference"><a href="#cite_note-Amin2005-21"><span>[</span>21<span>]</span></a></sup> AML must be carefully differentiated from "preleukemic" conditions such as <a href="/wiki/Myelodysplastic_syndrome" title="Myelodysplastic syndrome">myelodysplastic</a> or <a href="/wiki/Myeloproliferative_syndrome" title="Myeloproliferative syndrome" class="mw-redirect">myeloproliferative</a> syndromes, which are treated differently.</p>
<p>Because <a href="/wiki/Acute_promyelocytic_leukemia" title="Acute promyelocytic leukemia">acute promyelocytic leukemia</a> (APL) has the highest curability and requires a unique form of treatment, it is important to quickly establish or exclude the diagnosis of this subtype of leukemia. Fluorescent <i>in situ</i> hybridization performed on blood or bone marrow is often used for this purpose, as it readily identifies the <a href="/wiki/Chromosomal_translocation" title="Chromosomal translocation">chromosomal translocation</a> [t(15;17)(q22;q12);] that characterizes APL. There is also a need to molecularly detect the presence of PML/RARA fusion protein, which is an oncogenic product of that translocation. <sup id="cite_ref-22" class="reference"><a href="#cite_note-22"><span>[</span>22<span>]</span></a></sup></p>
<p>The two most commonly used classification schemata for AML are the older French-American-British (FAB) system and the newer <a href="/wiki/World_Health_Organization" title="World Health Organization">World Health Organization</a> (WHO) system.</p>
<h3><span class="mw-headline" id="World_Health_Organization">World Health Organization</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=8" title="Edit section: World Health Organization">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The <a href="/wiki/World_Health_Organization" title="World Health Organization">World Health Organization</a> (WHO) classification of acute myeloid leukemia attempts to be more clinically useful and to produce more meaningful prognostic information than the FAB criteria. Each of the WHO categories contains numerous descriptive subcategories of interest to the <a href="/wiki/Hematopathologist" title="Hematopathologist" class="mw-redirect">hematopathologist</a> and <a href="/wiki/Oncologist" title="Oncologist" class="mw-redirect">oncologist</a>; however, most of the clinically significant information in the WHO schema is communicated via categorization into one of the subtypes listed below.</p>
<p>The WHO subtypes of AML are:<sup id="cite_ref-23" class="reference"><a href="#cite_note-23"><span>[</span>23<span>]</span></a></sup></p>
<table class="wikitable">
<tr>
<th>Name</th>
<th>Description</th>
<th><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">ICD-O</a></th>
</tr>
<tr>
<td><b>Acute myeloid leukemia with recurrent genetic abnormalities</b></td>
<td>Includes:
<ul>
<li>AML with translocations between <a href="/wiki/Chromosome_8" title="Chromosome 8" class="mw-redirect">chromosome 8</a> and <a href="/wiki/Chromosome_21" title="Chromosome 21" class="mw-redirect">21</a> - [t(8;21)(q22;q22);] <a href="/wiki/RUNX1" title="RUNX1">RUNX1</a>/<a href="/wiki/RUNX1T1" title="RUNX1T1">RUNX1T1</a>; (ICD-O 9896/3);</li>
<li>AML with inversions in <a href="/wiki/Chromosome_16" title="Chromosome 16" class="mw-redirect">chromosome 16</a> - [inv(16)(p13.1q22)] or internal translocations in it - [t(16;16)(p13.1;q22);] <a href="/wiki/CBFB" title="CBFB">CBFB</a>/<a href="/wiki/MYH11" title="MYH11">MYH11</a>; (ICD-O 9871/3);</li>
<li><a href="/wiki/Acute_promyelocytic_leukemia" title="Acute promyelocytic leukemia">Acute promyelocytic leukemia</a> with translocations between <a href="/wiki/Chromosome_15" title="Chromosome 15" class="mw-redirect">chromosome 15</a> and <a href="/wiki/Chromosome_17" title="Chromosome 17" class="mw-redirect">17</a> - [t(15;17)(q22;q12);] <a href="/wiki/Retinoic_acid_receptor_alpha" title="Retinoic acid receptor alpha">RARA</a>/<a href="/wiki/Promyelocytic_leukemia_protein" title="Promyelocytic leukemia protein">PML</a>; (ICD-O 9866/3);</li>
<li>AML with translocations between <a href="/wiki/Chromosome_9" title="Chromosome 9" class="mw-redirect">chromosome 9</a> and <a href="/wiki/Chromosome_11" title="Chromosome 11" class="mw-redirect">11</a> - [t(9;11)(p22;q23);] <a href="/wiki/MLLT3" title="MLLT3">MLLT3</a>/<a href="/wiki/Myeloid/lymphoid_or_mixed-lineage_leukemia" title="Myeloid/lymphoid or mixed-lineage leukemia" class="mw-redirect">MLL</a>;</li>
<li>AML with translocations between <a href="/wiki/Chromosome_6" title="Chromosome 6" class="mw-redirect">chromosome 6</a> and <a href="/wiki/Chromosome_9" title="Chromosome 9" class="mw-redirect">9</a> - [t(6;9)(p23;q34);] <a href="/wiki/DEK_(gene)" title="DEK (gene)">DEK</a>/<a href="/wiki/NUP214" title="NUP214" class="mw-redirect">NUP214</a>;</li>
<li>AML with inversions in <a href="/wiki/Chromosome_3" title="Chromosome 3" class="mw-redirect">chromosome 3</a> - [inv(3)(q21q26.2)] or internal translocations in it - [t(3;3)(q21;q26.2);] <a href="/wiki/RPN1" title="RPN1">RPN1</a>/<a href="/wiki/EVI1" title="EVI1" class="mw-redirect">EVI1</a>;</li>
<li>Megakaryoblastic AML with translocations between <a href="/wiki/Chromosome_1" title="Chromosome 1" class="mw-redirect">chromosome 1</a> and <a href="/wiki/Chromosome_22" title="Chromosome 22" class="mw-redirect">22</a> - [t(1;22)(p13;q13);] <a href="/wiki/RBM15" title="RBM15">RBM15</a>/<a href="/wiki/MKL1" title="MKL1">MKL1</a>;</li>
<li>AML with mutated <a href="/wiki/NPM1" title="NPM1">NPM1</a></li>
<li>AML with mutated <a href="/wiki/CEBPA" title="CEBPA">CEBPA</a></li>
</ul>
</td>
<td>Multiple</td>
</tr>
<tr>
<td><b>AML with myelodysplasia-related changes</b></td>
<td>This category includes patients who have had a prior documented <a href="/wiki/Myelodysplastic_syndrome" title="Myelodysplastic syndrome">myelodysplastic syndrome</a> (MDS) or <a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">myeloproliferative disease</a> (MPD) that then has transformed into AML, or who have cytogenetic abnormalities characteristic for this type of AML (with previous history of MDS or MPD that has gone unnoticed in the past, but the cytogenetics is still suggestive of MDS/MPD history). This category of AML occurs most often in elderly patients and often has a worse prognosis. Includes:
<ul>
<li>AML with complex <a href="/wiki/Karyotype" title="Karyotype">karyotype</a></li>
<li>Unbalanced abnormalities
<ul>
<li>AML with deletions of <a href="/wiki/Chromosome_7" title="Chromosome 7" class="mw-redirect">chromosome 7</a> - [del(7q);]</li>
<li>AML with deletions of <a href="/wiki/Chromosome_5" title="Chromosome 5" class="mw-redirect">chromosome 5</a> - [del(5q);]</li>
<li>AML with unbalanced chromosomal aberrations in <a href="/wiki/Chromosome_17" title="Chromosome 17" class="mw-redirect">chromosome 17</a> - [i(17q)/t(17p);]</li>
<li>AML with deletions of <a href="/wiki/Chromosome_13" title="Chromosome 13" class="mw-redirect">chromosome 13</a> - [del(13q);]</li>
<li>AML with deletions of <a href="/wiki/Chromosome_11" title="Chromosome 11" class="mw-redirect">chromosome 11</a> - [del(11q);]</li>
<li>AML with unbalanced chromosomal aberrations in <a href="/wiki/Chromosome_12" title="Chromosome 12" class="mw-redirect">chromosome 12</a> - [del(12p)/t(12p);]</li>
<li>AML with deletions of <a href="/wiki/Chromosome_9" title="Chromosome 9" class="mw-redirect">chromosome 9</a> - [del(9q);]</li>
<li>AML with aberrations in <a href="/wiki/Chromosome_X" title="Chromosome X" class="mw-redirect">chromosome X</a> - [idic(X)(q13);]</li>
</ul>
</li>
<li>Balanced abnormalities
<ul>
<li>AML with translocations between <a href="/wiki/Chromosome_11" title="Chromosome 11" class="mw-redirect">chromosome 11</a> and <a href="/wiki/Chromosome_16" title="Chromosome 16" class="mw-redirect">16</a> - [t(11;16)(q23;q13.3);], unrelated to previous chemotherapy or ionizing radiation</li>
<li>AML with translocations between <a href="/wiki/Chromosome_3" title="Chromosome 3" class="mw-redirect">chromosome 3</a> and <a href="/wiki/Chromosome_21" title="Chromosome 21" class="mw-redirect">21</a> - [t(3;21)(q26.2;q22.1);], unrelated to previous chemotherapy or ionizing radiation</li>
<li>AML with translocations between <a href="/wiki/Chromosome_1" title="Chromosome 1" class="mw-redirect">chromosome 1</a> and <a href="/wiki/Chromosome_3" title="Chromosome 3" class="mw-redirect">3</a> - [t(1;3)(p36.3;q21.1);]</li>
<li>AML with translocations between <a href="/wiki/Chromosome_2" title="Chromosome 2" class="mw-redirect">chromosome 2</a> and <a href="/wiki/Chromosome_11" title="Chromosome 11" class="mw-redirect">11</a> - [t(2;11)(p21;q23);], unrelated to previous chemotherapy or ionizing radiation</li>
<li>AML with translocations between <a href="/wiki/Chromosome_5" title="Chromosome 5" class="mw-redirect">chromosome 5</a> and <a href="/wiki/Chromosome_12" title="Chromosome 12" class="mw-redirect">12</a> - [t(5;12)(q33;p12);]</li>
<li>AML with translocations between <a href="/wiki/Chromosome_5" title="Chromosome 5" class="mw-redirect">chromosome 5</a> and <a href="/wiki/Chromosome_7" title="Chromosome 7" class="mw-redirect">7</a> - [t(5;7)(q33;q11.2);]</li>
<li>AML with translocations between <a href="/wiki/Chromosome_5" title="Chromosome 5" class="mw-redirect">chromosome 5</a> and <a href="/wiki/Chromosome_17" title="Chromosome 17" class="mw-redirect">17</a> - [t(5;17)(q33;p13);]</li>
<li>AML with translocations between <a href="/wiki/Chromosome_5" title="Chromosome 5" class="mw-redirect">chromosome 5</a> and <a href="/wiki/Chromosome_10" title="Chromosome 10" class="mw-redirect">10</a> - [t(5;10)(q33;q21);]</li>
<li>AML with translocations between <a href="/wiki/Chromosome_3" title="Chromosome 3" class="mw-redirect">chromosome 3</a> and <a href="/wiki/Chromosome_5" title="Chromosome 5" class="mw-redirect">5</a> - [t(3;5)(q25;q34);]</li>
</ul>
</li>
</ul>
</td>
<td><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">M</a><a rel="nofollow" class="external text" href="http://www.progenetix.net/progenetix/I98953/">9895/3</a></td>
</tr>
<tr>
<td><b>Therapy-related myeloid neoplasms</b></td>
<td>This category includes patients who have had prior chemotherapy and/or radiation and subsequently develop AML or MDS. These leukemias may be characterized by specific chromosomal abnormalities, and often carry a worse prognosis.</td>
<td><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">M</a><a rel="nofollow" class="external text" href="http://www.progenetix.net/progenetix/I99203/">9920/3</a></td>
</tr>
<tr>
<td><b>Myeloid sarcoma</b></td>
<td>This category includes myeloid sarcoma.</td>
<td></td>
</tr>
<tr>
<td><b>Myeloid proliferations related to <a href="/wiki/Down_syndrome" title="Down syndrome">Down syndrome</a></b></td>
<td>This category includes so-called "transient abnormal myelopoiesis" and "Myeloid leukemia associated with Down syndrome"</td>
<td></td>
</tr>
<tr>
<td><b>Blastic plasmacytoid dendritic cell neoplasm</b></td>
<td>This category includes so-called "blastic plasmacytoid dendritic cell neoplasm"</td>
<td></td>
</tr>
<tr>
<td><b>AML not otherwise categorized</b></td>
<td>Includes subtypes of AML that do not fall into the above categories
<ul>
<li><a href="/wiki/AML_with_minimal_differentiation" title="AML with minimal differentiation" class="mw-redirect">AML with minimal differentiation</a></li>
<li><a href="/wiki/AML_without_maturation" title="AML without maturation" class="mw-redirect">AML without maturation</a></li>
<li><a href="/wiki/AML_with_maturation" title="AML with maturation" class="mw-redirect">AML with maturation</a></li>
<li><a href="/wiki/Acute_myelomonocytic_leukemia" title="Acute myelomonocytic leukemia">Acute myelomonocytic leukemia</a></li>
<li><a href="/wiki/Acute_monoblastic_and_monocytic_leukemia" title="Acute monoblastic and monocytic leukemia" class="mw-redirect">Acute monoblastic and monocytic leukemia</a></li>
<li><a href="/wiki/Acute_erythroid_leukemia" title="Acute erythroid leukemia">Acute erythroid leukemia</a></li>
<li><a href="/wiki/Acute_megakaryoblastic_leukemia" title="Acute megakaryoblastic leukemia">Acute megakaryoblastic leukemia</a></li>
<li><a href="/wiki/Acute_basophilic_leukemia" title="Acute basophilic leukemia">Acute basophilic leukemia</a></li>
<li><a href="/wiki/Acute_panmyelosis_with_myelofibrosis" title="Acute panmyelosis with myelofibrosis">Acute panmyelosis with myelofibrosis</a></li>
</ul>
</td>
<td><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">M</a><a rel="nofollow" class="external text" href="http://www.progenetix.net/progenetix/I98613/">9861/3</a></td>
</tr>
</table>
<p>Acute leukemias of ambiguous lineage (also known as mixed phenotype or <a href="/wiki/Biphenotypic_acute_leukemia" title="Biphenotypic acute leukemia" class="mw-redirect">biphenotypic acute leukemia</a>) occur when the leukemic cells can not be classified as either myeloid or lymphoid cells, or where both types of cells are present.</p>
<h3><span class="mw-headline" id="French-American-British">French-American-British</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=9" title="Edit section: French-American-British">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The <a href="/wiki/French-American-British_classification" title="French-American-British classification" class="mw-redirect">French-American-British (FAB) classification</a> system divides AML into eight subtypes, M0 through to M7, based on the type of cell from which the leukemia developed and its degree of maturity. This is done by examining the appearance of the <a href="/wiki/Malignant" title="Malignant" class="mw-redirect">malignant cells</a> with <a href="/wiki/Light_microscopy" title="Light microscopy" class="mw-redirect">light microscopy</a> and/or by using <a href="/wiki/Cytogenetics" title="Cytogenetics">cytogenetics</a> to characterize any underlying chromosomal abnormalities. The subtypes have varying prognoses and responses to therapy. Although the WHO classification (see above) may be more useful, the FAB system is still widely used.</p>
<p>Eight FAB subtypes were proposed in 1976.<sup id="cite_ref-24" class="reference"><a href="#cite_note-24"><span>[</span>24<span>]</span></a></sup></p>
<table class="wikitable">
<tr>
<th>Type</th>
<th>Name</th>
<th>Cytogenetics</th>
<th>Percentage of adult AML patients</th>
</tr>
<tr>
<td>M0</td>
<td><a href="/wiki/Acute_myeloblastic_leukemia,_minimally_differentiated" title="Acute myeloblastic leukemia, minimally differentiated" class="mw-redirect">acute myeloblastic leukemia, minimally differentiated</a></td>
<td></td>
<td>5%<sup id="cite_ref-medscape_25-0" class="reference"><a href="#cite_note-medscape-25"><span>[</span>25<span>]</span></a></sup></td>
</tr>
<tr>
<td>M1</td>
<td><a href="/wiki/Acute_myeloblastic_leukemia,_without_maturation" title="Acute myeloblastic leukemia, without maturation" class="mw-redirect">acute myeloblastic leukemia, without maturation</a></td>
<td></td>
<td>15%<sup id="cite_ref-medscape_25-1" class="reference"><a href="#cite_note-medscape-25"><span>[</span>25<span>]</span></a></sup></td>
</tr>
<tr>
<td>M2</td>
<td><a href="/wiki/Acute_myeloblastic_leukemia,_with_granulocytic_maturation" title="Acute myeloblastic leukemia, with granulocytic maturation" class="mw-redirect">acute myeloblastic leukemia, with granulocytic maturation</a></td>
<td>t(8;21)(q22;q22), t(6;9)</td>
<td>25%<sup id="cite_ref-medscape_25-2" class="reference"><a href="#cite_note-medscape-25"><span>[</span>25<span>]</span></a></sup></td>
</tr>
<tr>
<td>M3</td>
<td>promyelocytic, or <a href="/wiki/Acute_promyelocytic_leukemia" title="Acute promyelocytic leukemia">acute promyelocytic leukemia</a> (APL)</td>
<td>t(15;17)</td>
<td>10%<sup id="cite_ref-medscape_25-3" class="reference"><a href="#cite_note-medscape-25"><span>[</span>25<span>]</span></a></sup></td>
</tr>
<tr>
<td>M4</td>
<td><a href="/wiki/Acute_myelomonocytic_leukemia" title="Acute myelomonocytic leukemia">acute myelomonocytic leukemia</a></td>
<td>inv(16)(p13q22), del(16q)</td>
<td>20%<sup id="cite_ref-medscape_25-4" class="reference"><a href="#cite_note-medscape-25"><span>[</span>25<span>]</span></a></sup></td>
</tr>
<tr>
<td>M4eo</td>
<td>myelomonocytic together with bone marrow <a href="/wiki/Eosinophil" title="Eosinophil" class="mw-redirect">eosinophilia</a></td>
<td>inv(16), t(16;16)</td>
<td>5%<sup id="cite_ref-medscape_25-5" class="reference"><a href="#cite_note-medscape-25"><span>[</span>25<span>]</span></a></sup></td>
</tr>
<tr>
<td>M5</td>
<td><a href="/wiki/Acute_monoblastic_leukemia" title="Acute monoblastic leukemia" class="mw-redirect">acute monoblastic leukemia</a> (M5a) or <a href="/wiki/Acute_monocytic_leukemia" title="Acute monocytic leukemia">acute monocytic leukemia</a> (M5b)</td>
<td>del (11q), t(9;11), t(11;19)</td>
<td>10%<sup id="cite_ref-medscape_25-6" class="reference"><a href="#cite_note-medscape-25"><span>[</span>25<span>]</span></a></sup></td>
</tr>
<tr>
<td>M6</td>
<td><a href="/wiki/Acute_erythroid_leukemia" title="Acute erythroid leukemia">acute erythroid leukemias</a>, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b)</td>
<td></td>
<td>5%<sup id="cite_ref-medscape_25-7" class="reference"><a href="#cite_note-medscape-25"><span>[</span>25<span>]</span></a></sup></td>
</tr>
<tr>
<td>M7</td>
<td><a href="/wiki/Acute_megakaryoblastic_leukemia" title="Acute megakaryoblastic leukemia">acute megakaryoblastic leukemia</a></td>
<td>t(1;22)</td>
<td>5%<sup id="cite_ref-medscape_25-8" class="reference"><a href="#cite_note-medscape-25"><span>[</span>25<span>]</span></a></sup></td>
</tr>
</table>
<p>The morphologic subtypes of AML also include rare types not included in the FAB system, such as <a href="/wiki/Acute_basophilic_leukemia" title="Acute basophilic leukemia">acute basophilic leukemia</a>, which was proposed as a ninth subtype, M8, in 1999.<sup id="cite_ref-26" class="reference"><a href="#cite_note-26"><span>[</span>26<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Pathophysiology">Pathophysiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=10" title="Edit section: Pathophysiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Diagram_showing_the_cells_in_which_AML_starts_CRUK_297.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/c/cb/Diagram_showing_the_cells_in_which_AML_starts_CRUK_297.svg/220px-Diagram_showing_the_cells_in_which_AML_starts_CRUK_297.svg.png" width="220" height="279" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/c/cb/Diagram_showing_the_cells_in_which_AML_starts_CRUK_297.svg/330px-Diagram_showing_the_cells_in_which_AML_starts_CRUK_297.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/c/cb/Diagram_showing_the_cells_in_which_AML_starts_CRUK_297.svg/440px-Diagram_showing_the_cells_in_which_AML_starts_CRUK_297.svg.png 2x" data-file-width="291" data-file-height="369" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Diagram_showing_the_cells_in_which_AML_starts_CRUK_297.svg" class="internal" title="Enlarge"></a></div>
Diagram showing the cells where AML develops</div>
</div>
</div>
<p>The malignant cell in AML is the <a href="/wiki/Myeloblast" title="Myeloblast">myeloblast</a>. In normal <a href="/wiki/Haematopoiesis" title="Haematopoiesis">hematopoiesis</a>, the myeloblast is an immature precursor of <a href="/wiki/Myeloid" title="Myeloid">myeloid</a> white blood cells; a normal myeloblast will gradually mature into a mature white blood cell. In AML, though, a single myeloblast accumulates genetic changes which "freeze" the cell in its immature state and prevent <a href="/wiki/Cellular_differentiation" title="Cellular differentiation">differentiation</a>.<sup id="cite_ref-27" class="reference"><a href="#cite_note-27"><span>[</span>27<span>]</span></a></sup> Such a mutation alone does not cause leukemia; however, when such a "differentiation arrest" is <a href="/wiki/Knudson_hypothesis" title="Knudson hypothesis">combined with other mutations</a> which disrupt genes controlling <a href="/wiki/Cell_growth" title="Cell growth">proliferation</a>, the result is the uncontrolled growth of an immature clone of cells, leading to the clinical entity of AML.<sup id="cite_ref-28" class="reference"><a href="#cite_note-28"><span>[</span>28<span>]</span></a></sup></p>
<p>Much of the diversity and heterogeneity of AML stems is because leukemic transformation can occur at a number of different steps along the differentiation pathway.<sup id="cite_ref-29" class="reference"><a href="#cite_note-29"><span>[</span>29<span>]</span></a></sup> Modern classification schemes for AML recognize the characteristics and behavior of the leukemic cell (and the leukemia) may depend on the stage at which differentiation was halted.</p>
<p>Specific <a href="/wiki/Cytogenetics" title="Cytogenetics">cytogenetic</a> abnormalities can be found in many patients with AML; the types of chromosomal abnormalities often have <a href="/wiki/Prognosis" title="Prognosis">prognostic</a> significance.<sup id="cite_ref-30" class="reference"><a href="#cite_note-30"><span>[</span>30<span>]</span></a></sup> The chromosomal <a href="/wiki/Translocations" title="Translocations" class="mw-redirect">translocations</a> encode abnormal fusion <a href="/wiki/Proteins" title="Proteins" class="mw-redirect">proteins</a>, usually <a href="/wiki/Transcription_factors" title="Transcription factors" class="mw-redirect">transcription factors</a> whose altered properties may cause the "differentiation arrest".<sup id="cite_ref-31" class="reference"><a href="#cite_note-31"><span>[</span>31<span>]</span></a></sup> For example, in <a href="/wiki/Acute_promyelocytic_leukemia" title="Acute promyelocytic leukemia">acute promyelocytic leukemia</a>, the t(15;17) translocation produces a PML-RARα <a href="/wiki/Fusion_protein" title="Fusion protein">fusion protein</a> which binds to the <a href="/wiki/Retinoic_acid" title="Retinoic acid">retinoic acid</a> receptor element in the promoters of several myeloid-specific genes and inhibits myeloid differentiation.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32"><span>[</span>32<span>]</span></a></sup></p>
<p>The <a href="/wiki/Medical_sign" title="Medical sign">clinical signs</a> and symptoms of AML result from the growth of leukemic clone cells, which tends to displace or interfere with the development of normal blood cells in the bone marrow.<sup id="cite_ref-33" class="reference"><a href="#cite_note-33"><span>[</span>33<span>]</span></a></sup> This leads to <a href="/wiki/Neutropenia" title="Neutropenia">neutropenia</a>, <a href="/wiki/Anemia" title="Anemia">anemia</a>, and <a href="/wiki/Thrombocytopenia" title="Thrombocytopenia">thrombocytopenia</a>. The symptoms of AML are, in turn, often due to the low numbers of these normal blood elements. In rare cases, patients can develop a <a href="/wiki/Chloroma" title="Chloroma" class="mw-redirect">chloroma</a>, or solid tumor of leukemic cells outside the bone marrow, which can cause various symptoms depending on its location.<sup id="cite_ref-symptoms_2-3" class="reference"><a href="#cite_note-symptoms-2"><span>[</span>2<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Treatment">Treatment</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=11" title="Edit section: Treatment">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>First-line treatment of AML consists primarily of <a href="/wiki/Chemotherapy" title="Chemotherapy">chemotherapy</a>, and is divided into two phases: <b>induction</b> and <b>postremission</b> (or <b>consolidation</b>) therapy. The goal of induction therapy is to achieve a complete remission by reducing the number of leukemic cells to an undetectable level; the goal of consolidation therapy is to eliminate any residual undetectable disease and achieve a cure.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34"><span>[</span>34<span>]</span></a></sup> Hematopoietic stem cell transplantation is usually considered if induction chemotherapy fails or after a patient relapses, although transplantation is also sometimes used as front-line therapy for patients with high-risk disease.</p>
<h3><span class="mw-headline" id="Induction">Induction</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=12" title="Edit section: Induction">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>All FAB subtypes except M3 are usually given <a href="/wiki/Induction_chemotherapy" title="Induction chemotherapy">induction chemotherapy</a> with <a href="/wiki/Cytarabine" title="Cytarabine">cytarabine</a> (ara-C) and an <a href="/wiki/Anthracycline" title="Anthracycline">anthracycline</a> (most often <a href="/wiki/Daunorubicin" title="Daunorubicin">daunorubicin</a>).<sup id="cite_ref-treatment_35-0" class="reference"><a href="#cite_note-treatment-35"><span>[</span>35<span>]</span></a></sup> This induction chemotherapy regimen is known as "<a href="/wiki/7%2B3_(chemotherapy)" title="7+3 (chemotherapy)">7+3</a>" (or "3+7"), because the <a href="/wiki/Cytarabine" title="Cytarabine">cytarabine</a> is given as a continuous IV infusion for seven consecutive days while the <a href="/wiki/Anthracycline" title="Anthracycline">anthracycline</a> is given for three consecutive days as an <a href="/wiki/IV_push" title="IV push" class="mw-redirect">IV push</a>. Up to 70% of patients will achieve a remission with this protocol.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36"><span>[</span>36<span>]</span></a></sup> Other alternative induction regimens, including <a href="/wiki/R-HDAC" title="R-HDAC">high-dose cytarabine</a> alone, <a href="/wiki/FLAG_(chemotherapy)" title="FLAG (chemotherapy)">FLAG-like regimens</a> or investigational agents, may also be used.<sup id="cite_ref-37" class="reference"><a href="#cite_note-37"><span>[</span>37<span>]</span></a></sup><sup id="cite_ref-38" class="reference"><a href="#cite_note-38"><span>[</span>38<span>]</span></a></sup> Because of the toxic effects of therapy, including <a href="/wiki/Myelosuppression" title="Myelosuppression" class="mw-redirect">myelosuppression</a> and an increased risk of infection, induction chemotherapy may not be offered to the very elderly, and the options may include less intense chemotherapy or <a href="/wiki/Palliative_care" title="Palliative care">palliative care</a>.</p>
<p>The M3 subtype of AML, also known as <a href="/wiki/Acute_promyelocytic_leukemia" title="Acute promyelocytic leukemia">acute promyelocytic leukemia</a> (APL), is almost universally treated with the drug all-<i>trans</i>-retinoic acid (<a href="/wiki/ATRA" title="ATRA" class="mw-redirect">ATRA</a>) in addition to induction chemotherapy, usually an anthracycline.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39"><span>[</span>39<span>]</span></a></sup><sup id="cite_ref-40" class="reference"><a href="#cite_note-40"><span>[</span>40<span>]</span></a></sup><sup id="cite_ref-41" class="reference"><a href="#cite_note-41"><span>[</span>41<span>]</span></a></sup> Care must be taken to prevent disseminated intravascular coagulation (<a href="/wiki/Disseminated_intravascular_coagulation" title="Disseminated intravascular coagulation">DIC</a>), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation. APL is eminently curable, with well-documented treatment protocols.</p>
<p>The goal of the induction phase is to reach a complete remission. Complete remission does not mean the disease has been cured; rather, it signifies no disease can be detected with available diagnostic methods.<sup id="cite_ref-treatment_35-1" class="reference"><a href="#cite_note-treatment-35"><span>[</span>35<span>]</span></a></sup> Complete remission is obtained in about 50%–75% of newly diagnosed adults, although this may vary based on the prognostic factors described above.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42"><span>[</span>42<span>]</span></a></sup> The length of remission depends on the prognostic features of the original leukemia. In general, all remissions will fail without additional consolidation therapy.<sup id="cite_ref-43" class="reference"><a href="#cite_note-43"><span>[</span>43<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Consolidation">Consolidation</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=13" title="Edit section: Consolidation">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Even after complete remission is achieved, leukemic cells likely remain in numbers too small to be detected with current diagnostic techniques. If no further postremission or consolidation therapy is given, almost all patients will eventually relapse.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44"><span>[</span>44<span>]</span></a></sup> Therefore, more therapy is necessary to eliminate nondetectable disease and prevent relapse&#160;— that is, to achieve a cure.</p>
<p>The specific type of postremission therapy is individualized based on a patient's prognostic factors (see above) and general health. For good-prognosis leukemias (i.e. inv(16), t(8;21), and t(15;17)), patients will typically undergo an additional three to five courses of intensive chemotherapy, known as consolidation chemotherapy.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45"><span>[</span>45<span>]</span></a></sup><sup id="cite_ref-nccn_46-0" class="reference"><a href="#cite_note-nccn-46"><span>[</span>46<span>]</span></a></sup> For patients at high risk of relapse (e.g. those with high-risk cytogenetics, underlying MDS, or therapy-related AML), <a href="/wiki/Bone_marrow_transplant" title="Bone marrow transplant" class="mw-redirect">allogeneic stem cell transplantation</a> is usually recommended if the patient is able to tolerate a transplant and has a suitable donor. The best postremission therapy for intermediate-risk AML (normal cytogenetics or cytogenetic changes not falling into good-risk or high-risk groups) is less clear and depends on the specific situation, including the age and overall health of the patient, the patient's personal values, and whether a suitable <a href="/wiki/Stem_cell" title="Stem cell">stem cell</a> donor is available.<sup id="cite_ref-nccn_46-1" class="reference"><a href="#cite_note-nccn-46"><span>[</span>46<span>]</span></a></sup></p>
<p>For patients who are not eligible for a stem cell transplant, immunotherapy with a combination of histamine dihydrochloride (<a href="/wiki/Ceplene" title="Ceplene" class="mw-redirect">Ceplene</a>) and <a href="/wiki/Interleukin_2" title="Interleukin 2">interleukin 2</a> (Proleukin) after the completion of consolidation has been shown to reduce the absolute relapse risk by 14%, translating to a 50% increase in the likelihood of maintained remission.<sup id="cite_ref-47" class="reference"><a href="#cite_note-47"><span>[</span>47<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Relapsed_AML">Relapsed AML</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=14" title="Edit section: Relapsed AML">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>For patients with relapsed AML, the only proven potentially curative therapy is a <a href="/wiki/Hematopoietic_stem_cell_transplant" title="Hematopoietic stem cell transplant" class="mw-redirect">hematopoietic stem cell transplant</a>, if one has not already been performed.<sup id="cite_ref-relapse_48-0" class="reference"><a href="#cite_note-relapse-48"><span>[</span>48<span>]</span></a></sup><sup id="cite_ref-49" class="reference"><a href="#cite_note-49"><span>[</span>49<span>]</span></a></sup><sup id="cite_ref-50" class="reference"><a href="#cite_note-50"><span>[</span>50<span>]</span></a></sup> In 2000, the <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">monoclonal antibody</a>-linked cytotoxic agent <a href="/wiki/Gemtuzumab_ozogamicin" title="Gemtuzumab ozogamicin">gemtuzumab ozogamicin</a> (Mylotarg) was approved in the United States for patients aged more than 60 years with relapsed AML who are not candidates for high-dose chemotherapy.<sup id="cite_ref-51" class="reference"><a href="#cite_note-51"><span>[</span>51<span>]</span></a></sup> This drug was voluntarily withdrawn from the market by its manufacturer, Pfizer in 2010.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52"><span>[</span>52<span>]</span></a></sup></p>
<p>Since treatment options for relapsed AML are so limited, <a href="/wiki/Palliative_care" title="Palliative care">palliative care</a> may be offered.</p>
<h4><span class="mw-headline" id="Clinical_trials">Clinical trials</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=15" title="Edit section: Clinical trials">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Patients with relapsed AML who are not candidates for stem cell transplantion, or who have relapsed after a stem cell transplant, may be offered treatment in a <a href="/wiki/Clinical_trial" title="Clinical trial">clinical trial</a>, as conventional treatment options are limited. Agents under investigation include cytotoxic drugs such as <a href="/wiki/Clofarabine" title="Clofarabine">clofarabine</a>, as well as <a href="/wiki/Targeted_therapy" title="Targeted therapy">targeted therapies</a>, such as <a href="/wiki/Farnesyltransferase_inhibitor" title="Farnesyltransferase inhibitor">farnesyl transferase inhibitors</a>, decitabine, and inhibitors of MDR1 (<a href="/wiki/Multidrug_resistance" title="Multidrug resistance" class="mw-redirect">multidrug-resistance</a> protein).</p>
<h4><span class="mw-headline" id="Relapsed_APL">Relapsed APL</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=16" title="Edit section: Relapsed APL">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>For relapsed acute promyelocytic leukemia (APL), <a href="/wiki/Arsenic_trioxide" title="Arsenic trioxide">arsenic trioxide</a> has been tested in trials and approved by the <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">US FDA</a>. Like ATRA, arsenic trioxide does not work with other subtypes of AML.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53"><span>[</span>53<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Prognosis">Prognosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=17" title="Edit section: Prognosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:199px;"><a href="/wiki/File:9;11.rhyax.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/c/c7/9%3B11.rhyax.jpg" width="197" height="246" class="thumbimage" data-file-width="197" data-file-height="246" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:9;11.rhyax.jpg" class="internal" title="Enlarge"></a></div>
Chromosomal translocation (9;11), associated with AML</div>
</div>
</div>
<p>Acute myeloid leukemia is a curable disease; the chance of cure for a specific patient depends on a number of prognostic factors.<sup id="cite_ref-prog_54-0" class="reference"><a href="#cite_note-prog-54"><span>[</span>54<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Cytogenetics">Cytogenetics</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=18" title="Edit section: Cytogenetics">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The single most important prognostic factor in AML is <a href="/wiki/Cytogenetics" title="Cytogenetics">cytogenetics</a>, or the chromosomal structure of the leukemic cell. Certain cytogenetic abnormalities are associated with very good outcomes (for example, the (15;17) translocation in <a href="/wiki/Acute_promyelocytic_leukemia" title="Acute promyelocytic leukemia">acute promyelocytic leukemia</a>). About half of AML patients have "normal" cytogenetics; they fall into an intermediate risk group. A number of other cytogenetic abnormalities are known to associate with a poor prognosis and a high risk of relapse after treatment.<sup id="cite_ref-55" class="reference"><a href="#cite_note-55"><span>[</span>55<span>]</span></a></sup><sup id="cite_ref-56" class="reference"><a href="#cite_note-56"><span>[</span>56<span>]</span></a></sup><sup id="cite_ref-57" class="reference"><a href="#cite_note-57"><span>[</span>57<span>]</span></a></sup></p>
<p>The first publication to address cytogenetics and prognosis was the MRC trial of 1998:<sup id="cite_ref-58" class="reference"><a href="#cite_note-58"><span>[</span>58<span>]</span></a></sup></p>
<table class="wikitable">
<tr>
<th>Risk Category</th>
<th>Abnormality</th>
<th>5-year survival</th>
<th>Relapse rate</th>
</tr>
<tr>
<td>Good</td>
<td>t(8;21), t(15;17), inv(16)</td>
<td>70%</td>
<td>33%</td>
</tr>
<tr>
<td>Intermediate</td>
<td>Normal, +8, +21, +22, del(7q), del(9q), Abnormal 11q23, all other structural or numerical changes</td>
<td>48%</td>
<td>50%</td>
</tr>
<tr>
<td>Poor</td>
<td>-5, -7, del(5q), Abnormal 3q, Complex cytogenetics</td>
<td>15%</td>
<td>78%</td>
</tr>
</table>
<p>Later, the <a href="/wiki/Southwest_Oncology_Group" title="Southwest Oncology Group" class="mw-redirect">Southwest Oncology Group</a> and <a href="/wiki/Eastern_Cooperative_Oncology_Group" title="Eastern Cooperative Oncology Group">Eastern Cooperative Oncology Group</a><sup id="cite_ref-59" class="reference"><a href="#cite_note-59"><span>[</span>59<span>]</span></a></sup> and, later still, <a href="/wiki/Cancer_and_Leukemia_Group_B" title="Cancer and Leukemia Group B">Cancer and Leukemia Group B</a> published other, mostly overlapping lists of cytogenetics prognostication in leukemia.<sup id="cite_ref-60" class="reference"><a href="#cite_note-60"><span>[</span>60<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Myelodysplastic_syndrome">Myelodysplastic syndrome</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=19" title="Edit section: Myelodysplastic syndrome">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>AML which arises from a pre-existing <a href="/wiki/Myelodysplastic_syndrome" title="Myelodysplastic syndrome">myelodysplastic syndrome</a> (MDS) or <a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">myeloproliferative disease</a> (so-called secondary AML) has a worse <a href="/wiki/Prognosis" title="Prognosis">prognosis</a>, as does treatment-related AML arising after chemotherapy for another previous malignancy. Both of these entities are associated with a high rate of unfavorable cytogenetic abnormalities.<sup id="cite_ref-61" class="reference"><a href="#cite_note-61"><span>[</span>61<span>]</span></a></sup><sup id="cite_ref-62" class="reference"><a href="#cite_note-62"><span>[</span>62<span>]</span></a></sup><sup id="cite_ref-63" class="reference"><a href="#cite_note-63"><span>[</span>63<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Other_prognostic_markers">Other prognostic markers</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=20" title="Edit section: Other prognostic markers">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In some studies, age &gt;60 years and elevated <a href="/wiki/Lactate_dehydrogenase" title="Lactate dehydrogenase">lactate dehydrogenase</a> level were also associated with poorer outcomes.<sup id="cite_ref-64" class="reference"><a href="#cite_note-64"><span>[</span>64<span>]</span></a></sup> As with most forms of cancer, <a href="/wiki/Performance_status" title="Performance status">performance status</a> (i.e. the general physical condition and activity level of the patient) plays a major role in prognosis as well.</p>
<h4><span class="mw-headline" id="Genotype">Genotype</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=21" title="Edit section: Genotype">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p><i><a href="/wiki/FLT3" title="FLT3" class="mw-redirect">FLT3</a></i> internal tandem duplications (ITDs) have been shown to confer a poorer prognosis in AML.<sup id="cite_ref-65" class="reference"><a href="#cite_note-65"><span>[</span>65<span>]</span></a></sup> Treating these patients with more aggressive therapy, such as stem-cell transplantation in first remission, has not been shown to enhance long-term survival. ITDs of <a href="/wiki/FLT3" title="FLT3" class="mw-redirect">FLT3</a> may be associated with <a href="/wiki/Leukostasis" title="Leukostasis">leukostasis</a>.<sup id="cite_ref-pmid17942876_66-0" class="reference"><a href="#cite_note-pmid17942876-66"><span>[</span>66<span>]</span></a></sup> In 2012 <a href="/wiki/FLT3_inhibitor" title="FLT3 inhibitor" class="mw-redirect">FLT3 inhibitor</a> <a href="/wiki/Quizartinib" title="Quizartinib">quizartinib</a> had good phase II trial results in AML patients with FLT3-ITD mutations.</p>
<p>Researchers are investigating the clinical significance of <i><a href="/wiki/CD117" title="CD117">c-KIT</a></i> mutations in AML.<sup id="cite_ref-67" class="reference"><a href="#cite_note-67"><span>[</span>67<span>]</span></a></sup> These are prevalent, and clinically relevant because of the availability of <a href="/wiki/Tyrosine_kinase_inhibitors" title="Tyrosine kinase inhibitors" class="mw-redirect">tyrosine kinase inhibitors</a>, such as <a href="/wiki/Imatinib" title="Imatinib">imatinib</a> and <a href="/wiki/Sunitinib" title="Sunitinib">sunitinib</a> that can block the activity of <i>c-KIT</i> pharmacologically.</p>
<p>Other genes being investigated as prognostic factors or therapeutic targets include <i><a href="/wiki/CEBPA" title="CEBPA">CEBPA</a></i>, <i><a href="/wiki/BAALC" title="BAALC">BAALC</a></i>, <i><a href="/wiki/ERG_(gene)" title="ERG (gene)">ERG</a></i>, and <i><a href="/wiki/NPM1" title="NPM1">NPM1</a></i>.</p>
<h3><span class="mw-headline" id="Expectation_of_cure">Expectation of cure</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=22" title="Edit section: Expectation of cure">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Survival_curve_by_age_at_diagnosis_-_cancer_seer_gov_-_faststats.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/3/37/Survival_curve_by_age_at_diagnosis_-_cancer_seer_gov_-_faststats.jpg/220px-Survival_curve_by_age_at_diagnosis_-_cancer_seer_gov_-_faststats.jpg" width="220" height="256" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/en/thumb/3/37/Survival_curve_by_age_at_diagnosis_-_cancer_seer_gov_-_faststats.jpg/330px-Survival_curve_by_age_at_diagnosis_-_cancer_seer_gov_-_faststats.jpg 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/3/37/Survival_curve_by_age_at_diagnosis_-_cancer_seer_gov_-_faststats.jpg/440px-Survival_curve_by_age_at_diagnosis_-_cancer_seer_gov_-_faststats.jpg 2x" data-file-width="650" data-file-height="755" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Survival_curve_by_age_at_diagnosis_-_cancer_seer_gov_-_faststats.jpg" class="internal" title="Enlarge"></a></div>
Expected survival upon diagnosis of acute myeloid leukemia in the United States</div>
</div>
</div>
<p>Cure rates in clinical trials have ranged from 20–45%;<sup id="cite_ref-68" class="reference"><a href="#cite_note-68"><span>[</span>68<span>]</span></a></sup><sup id="cite_ref-69" class="reference"><a href="#cite_note-69"><span>[</span>69<span>]</span></a></sup> although clinical trials often include only younger patients and those able to tolerate aggressive therapies. The overall cure rate for all patients with AML (including the elderly and those unable to tolerate aggressive therapy) is likely lower. Cure rates for promyelocytic leukemia can be as high as 98%.<sup id="cite_ref-70" class="reference"><a href="#cite_note-70"><span>[</span>70<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Epidemiology">Epidemiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=23" title="Edit section: Epidemiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Acute myeloid leukemia is a relatively rare cancer. There are approximately 10,500 new cases each year in the United States, and the <a href="/wiki/Incidence_(epidemiology)" title="Incidence (epidemiology)">incidence</a> rate has remained stable from 1995 through 2005. AML accounts for 1.2% of all cancer deaths in the United States.<sup id="cite_ref-cancerstats_1-1" class="reference"><a href="#cite_note-cancerstats-1"><span>[</span>1<span>]</span></a></sup></p>
<p>The incidence of AML increases with age; the median age at diagnosis is 63 years. AML accounts for about 90% of all acute leukemias in adults, but is rare in children.<sup id="cite_ref-cancerstats_1-2" class="reference"><a href="#cite_note-cancerstats-1"><span>[</span>1<span>]</span></a></sup> The rate of <i>therapy-related AML</i> (that is, AML caused by previous chemotherapy) is rising; therapy-related disease currently accounts for about 10–20% of all cases of AML.<sup id="cite_ref-71" class="reference"><a href="#cite_note-71"><span>[</span>71<span>]</span></a></sup> AML is slightly more common in men, with a male-to-female ratio of 1.3:1.<sup id="cite_ref-72" class="reference"><a href="#cite_note-72"><span>[</span>72<span>]</span></a></sup></p>
<p>There is some geographic variation in the incidence of AML. In adults, the highest rates are seen in North America, Europe, and Oceania, while adult AML is rarer in Asia and Latin America.<sup id="cite_ref-73" class="reference"><a href="#cite_note-73"><span>[</span>73<span>]</span></a></sup><sup id="cite_ref-74" class="reference"><a href="#cite_note-74"><span>[</span>74<span>]</span></a></sup> In contrast, childhood AML is less common in North America and India than in other parts of Asia.<sup id="cite_ref-75" class="reference"><a href="#cite_note-75"><span>[</span>75<span>]</span></a></sup> These differences may be due to <a href="/wiki/Population_genetics" title="Population genetics">population genetics</a>, <a href="/wiki/Environmental_factor" title="Environmental factor">environmental factors</a>, or a combination of the two.</p>
<h3><span class="mw-headline" id="UK">UK</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=24" title="Edit section: UK">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>AML accounts for 34% of all leukaemia cases in the UK, and around 2,900 people were diagnosed with the disease in 2011.<sup id="cite_ref-76" class="reference"><a href="#cite_note-76"><span>[</span>76<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="History">History</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=25" title="Edit section: History">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Alfred_Velpeau_01.JPG" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/f/f3/Alfred_Velpeau_01.JPG/220px-Alfred_Velpeau_01.JPG" width="220" height="309" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/f3/Alfred_Velpeau_01.JPG/330px-Alfred_Velpeau_01.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/f/f3/Alfred_Velpeau_01.JPG 2x" data-file-width="356" data-file-height="500" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Alfred_Velpeau_01.JPG" class="internal" title="Enlarge"></a></div>
Alfred Velpeau</div>
</div>
</div>
<p>The first published description of a case of leukemia in medical literature dates to 1827, when French physician <a href="/wiki/Alfred-Armand-Louis-Marie_Velpeau" title="Alfred-Armand-Louis-Marie Velpeau">Alfred-Armand-Louis-Marie Velpeau</a> described a 63-year-old florist who developed an illness characterized by fever, weakness, <a href="/wiki/Nephrolithiasis" title="Nephrolithiasis" class="mw-redirect">urinary stones</a>, and substantial <a href="/wiki/Hepatosplenomegaly" title="Hepatosplenomegaly">enlargement of the liver and spleen</a>. Velpeau noted the blood of this patient had a consistency "like gruel", and speculated the appearance of the blood was due to white corpuscles.<sup id="cite_ref-77" class="reference"><a href="#cite_note-77"><span>[</span>77<span>]</span></a></sup> In 1845, a series of patients who died with enlarged spleens and changes in the "colors and consistencies of their blood" was reported by the <a href="/wiki/Edinburgh" title="Edinburgh">Edinburgh</a>-based <a href="/wiki/Pathologist" title="Pathologist" class="mw-redirect">pathologist</a> J.H. Bennett; he used the term "leucocythemia" to describe this pathological condition.<sup id="cite_ref-78" class="reference"><a href="#cite_note-78"><span>[</span>78<span>]</span></a></sup></p>
<p>The term "leukemia" was coined by <a href="/wiki/Rudolf_Virchow" title="Rudolf Virchow">Rudolf Virchow</a>, the renowned German <a href="/wiki/Pathologist" title="Pathologist" class="mw-redirect">pathologist</a>, in 1856. As a pioneer in the use of the <a href="/wiki/Light_microscope" title="Light microscope" class="mw-redirect">light microscope</a> in pathology, Virchow was the first to describe the abnormal excess of white blood cells in patients with the clinical syndrome described by Velpeau and Bennett. As Virchow was uncertain of the <a href="/wiki/Etiology" title="Etiology">etiology</a> of the white blood cell excess, he used the purely descriptive term "leukemia" (Greek: "white blood") to refer to the condition.<sup id="cite_ref-79" class="reference"><a href="#cite_note-79"><span>[</span>79<span>]</span></a></sup></p>
<p>Further advances in the understanding of acute myeloid leukemia occurred rapidly with the development of new technology. In 1877, <a href="/wiki/Paul_Ehrlich" title="Paul Ehrlich">Paul Ehrlich</a> developed a technique of <a href="/wiki/Staining_(biology)" title="Staining (biology)" class="mw-redirect">staining</a> blood films which allowed him to describe in detail normal and abnormal white blood cells. <a href="/wiki/Wilhelm_Ebstein" title="Wilhelm Ebstein">Wilhelm Ebstein</a> introduced the term "acute leukemia" in 1889 to differentiate rapidly progressive and fatal leukemias from the more <a href="/w/index.php?title=Indolent_condition&amp;action=edit&amp;redlink=1" class="new" title="Indolent condition (page does not exist)">indolent</a> <a href="/wiki/Chronic_leukemia" title="Chronic leukemia">chronic leukemias</a>.<sup id="cite_ref-80" class="reference"><a href="#cite_note-80"><span>[</span>80<span>]</span></a></sup> The term "myeloid" was coined by <a href="/wiki/Franz_Ernst_Christian_Neumann" title="Franz Ernst Christian Neumann">Franz Ernst Christian Neumann</a> in 1869, as he was the first to recognize white blood cells were made in the bone marrow (<a href="/wiki/Ancient_Greek" title="Ancient Greek">Greek</a>: µυєλός, <i>myelos</i> = (bone) marrow) as opposed to the <a href="/wiki/Spleen" title="Spleen">spleen</a>. The technique of <a href="/wiki/Bone_marrow_examination" title="Bone marrow examination">bone marrow examination</a> to diagnose leukemia was first described in 1879 by Mosler.<sup id="cite_ref-81" class="reference"><a href="#cite_note-81"><span>[</span>81<span>]</span></a></sup> Finally, in 1900, the <a href="/wiki/Myeloblast" title="Myeloblast">myeloblast</a>, which is the malignant cell in AML, was characterized by <a href="/wiki/Otto_Naegeli" title="Otto Naegeli">Otto Naegeli</a>, who divided the leukemias into myeloid and lymphocytic.<sup id="cite_ref-82" class="reference"><a href="#cite_note-82"><span>[</span>82<span>]</span></a></sup><sup id="cite_ref-83" class="reference"><a href="#cite_note-83"><span>[</span>83<span>]</span></a></sup></p>
<p>In 2008, AML became the first cancer genome to be fully <a href="/wiki/DNA_sequencing" title="DNA sequencing">sequenced</a>. DNA extracted from leukemic cells were compared to unaffected skin.<sup id="cite_ref-84" class="reference"><a href="#cite_note-84"><span>[</span>84<span>]</span></a></sup> The leukemic cells contained acquired mutations in several genes that had not previously been associated with the disease.</p>
<h2><span class="mw-headline" id="Pregnancy">Pregnancy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=26" title="Edit section: Pregnancy">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Leukemia is rarely associated with pregnancy, affecting only about 1 in 10,000 pregnant women.<sup id="cite_ref-Shapira_85-0" class="reference"><a href="#cite_note-Shapira-85"><span>[</span>85<span>]</span></a></sup> How it is handled depends primarily on the type of leukemia. Acute leukemias normally require prompt, aggressive treatment, despite significant risks of <a href="/wiki/Pregnancy_loss" title="Pregnancy loss" class="mw-redirect">pregnancy loss</a> and <a href="/wiki/Birth_defect" title="Birth defect" class="mw-redirect">birth defects</a>, especially if chemotherapy is given during the developmentally sensitive <a href="/wiki/First_trimester" title="First trimester" class="mw-redirect">first trimester</a>.<sup id="cite_ref-Shapira_85-1" class="reference"><a href="#cite_note-Shapira-85"><span>[</span>85<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=27" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-cancerstats-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-cancerstats_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-cancerstats_1-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-cancerstats_1-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Jemal A, Thomas A, Murray T, Thun M (2002). "Cancer statistics, 2002". <i>CA Cancer J Clin</i> <b>52</b> (1): 23–47. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.3322%2Fcanjclin.52.1.23">10.3322/canjclin.52.1.23</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11814064">11814064</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Cancer+statistics%2C+2002&amp;rft.au=Jemal+A%2C+Thomas+A%2C+Murray+T%2C+Thun+M&amp;rft.aulast=Jemal+A%2C+Thomas+A%2C+Murray+T%2C+Thun+M&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.3322%2Fcanjclin.52.1.23&amp;rft_id=info%3Apmid%2F11814064&amp;rft.issue=1&amp;rft.jtitle=CA+Cancer+J+Clin&amp;rft.pages=23-47&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=52" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-symptoms-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-symptoms_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-symptoms_2-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-symptoms_2-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-symptoms_2-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Hoffman, Ronald (2005). <i>Hematology: Basic Principles and Practice</i> (4th. ed.). <a href="/wiki/St_Louis,_Missouri" title="St Louis, Missouri" class="mw-redirect">St. Louis, Mo.</a>: <a href="/wiki/Churchill_Livingstone" title="Churchill Livingstone">Elsevier Churchill Livingstone</a>. pp.&#160;1074–75. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-443-06629-9" title="Special:BookSources/0-443-06629-9">0-443-06629-9</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.aufirst=Ronald&amp;rft.au=Hoffman%2C+Ronald&amp;rft.aulast=Hoffman&amp;rft.btitle=Hematology%3A+Basic+Principles+and+Practice&amp;rft.date=2005&amp;rft.edition=4th.&amp;rft.genre=book&amp;rft.isbn=0-443-06629-9&amp;rft.pages=1074-75&amp;rft.place=St.+Louis%2C+Mo.&amp;rft.pub=Elsevier+Churchill+Livingstone&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-3">^</a></b></span> <span class="reference-text"><span class="citation book">Abeloff, Martin (2004). <i>Clinical Oncology</i> (3rd. ed.). <a href="/wiki/St_Louis,_Missouri" title="St Louis, Missouri" class="mw-redirect">St. Louis, Mo.</a>: <a href="/wiki/Churchill_Livingstone" title="Churchill Livingstone">Elsevier Churchill Livingstone</a>. p.&#160;2834. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-443-06629-9" title="Special:BookSources/0-443-06629-9">0-443-06629-9</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.au=Abeloff%2C+Martin&amp;rft.aufirst=Martin&amp;rft.aulast=Abeloff&amp;rft.btitle=Clinical+Oncology&amp;rft.date=2004&amp;rft.edition=3rd.&amp;rft.genre=book&amp;rft.isbn=0-443-06629-9&amp;rft.pages=2834&amp;rft.place=St.+Louis%2C+Mo.&amp;rft.pub=Elsevier+Churchill+Livingstone&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-4">^</a></b></span> <span class="reference-text"><span class="citation journal">Sanz GF, Sanz MA, Vallespí T, Cañizo MC, Torrabadella M, García S, Irriguible D, San Miguel JF (1989). "Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients". <i>Blood</i> <b>74</b> (1): 395–408. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2752119">2752119</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Two+regression+models+and+a+scoring+system+for+predicting+survival+and+planning+treatment+in+myelodysplastic+syndromes%3A+a+multivariate+analysis+of+prognostic+factors+in+370+patients&amp;rft.aulast=Sanz+GF%2C+Sanz+MA%2C+Vallesp%C3%AD+T%2C+Ca%C3%B1izo+MC%2C+Torrabadella+M%2C+Garc%C3%ADa+S%2C+Irriguible+D%2C+San+Miguel+JF&amp;rft.au=Sanz+GF%2C+Sanz+MA%2C+Vallesp%C3%AD+T%2C+Ca%C3%B1izo+MC%2C+Torrabadella+M%2C+Garc%C3%ADa+S%2C+Irriguible+D%2C+San+Miguel+JF&amp;rft.date=1989&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F2752119&amp;rft.issue=1&amp;rft.jtitle=Blood&amp;rft.pages=395-408&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=74" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><span class="citation journal">Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD (1986). "Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7". <i>J Clin Oncol</i> <b>4</b> (3): 325–45. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3950675">3950675</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Clinical+and+cytogenetic+correlations+in+63+patients+with+therapy-related+myelodysplastic+syndromes+and+acute+nonlymphocytic+leukemia%3A+further+evidence+for+characteristic+abnormalities+of+chromosomes+no.+5+and+7&amp;rft.aulast=Le+Beau+MM%2C+Albain+KS%2C+Larson+RA%2C+Vardiman+JW%2C+Davis+EM%2C+Blough+RR%2C+Golomb+HM%2C+Rowley+JD&amp;rft.au=Le+Beau+MM%2C+Albain+KS%2C+Larson+RA%2C+Vardiman+JW%2C+Davis+EM%2C+Blough+RR%2C+Golomb+HM%2C+Rowley+JD&amp;rft.date=1986&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F3950675&amp;rft.issue=3&amp;rft.jtitle=J+Clin+Oncol&amp;rft.pages=325-45&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=4" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text"><span class="citation journal">Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Ziemin-van der Poel S, Kaneko Y, Morgan R, Sandberg AA (1993). "Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations". <i>N Engl J Med</i> <b>329</b> (13): 909–14. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJM199309233291302">10.1056/NEJM199309233291302</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8361504">8361504</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Rearrangement+of+the+MLL+gene+in+acute+lymphoblastic+and+acute+myeloid+leukemias+with+11q23+chromosomal+translocations&amp;rft.aulast=Thirman+MJ%2C+Gill+HJ%2C+Burnett+RC%2C+Mbangkollo+D%2C+McCabe+NR%2C+Kobayashi+H%2C+Ziemin-van+der+Poel+S%2C+Kaneko+Y%2C+Morgan+R%2C+Sandberg+AA&amp;rft.au=Thirman+MJ%2C+Gill+HJ%2C+Burnett+RC%2C+Mbangkollo+D%2C+McCabe+NR%2C+Kobayashi+H%2C+Ziemin-van+der+Poel+S%2C+Kaneko+Y%2C+Morgan+R%2C+Sandberg+AA&amp;rft.date=1993&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM199309233291302&amp;rft_id=info%3Apmid%2F8361504&amp;rft.issue=13&amp;rft.jtitle=N+Engl+J+Med&amp;rft.pages=909-14&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=329" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><span class="citation journal">Austin H, Delzell E, Cole P (1988). "Benzene and leukemia. A review of the literature and a risk assessment". <i>Am J Epidemiol</i> <b>127</b> (3): 419–39. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3277397">3277397</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Benzene+and+leukemia.+A+review+of+the+literature+and+a+risk+assessment&amp;rft.au=Austin+H%2C+Delzell+E%2C+Cole+P&amp;rft.aulast=Austin+H%2C+Delzell+E%2C+Cole+P&amp;rft.date=1988&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F3277397&amp;rft.issue=3&amp;rft.jtitle=Am+J+Epidemiol&amp;rft.pages=419-39&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=127" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text">Linet, MS. The Leukemias: Epidemiologic Aspects. <a href="/wiki/Oxford_University_Press" title="Oxford University Press">Oxford University Press</a>, New York 1985.</span></li>
<li id="cite_note-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-9">^</a></b></span> <span class="reference-text"><span class="citation journal">Bizzozero OJ, Johnson KG, Ciocco A (1966). "Radiation-related leukemia in Hiroshima and Nagasaki, 1946–1964. I. Distribution, incidence and appearance time". <i>N Engl J Med</i> <b>274</b> (20): 1095–101. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJM196605192742001">10.1056/NEJM196605192742001</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/5932020">5932020</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Radiation-related+leukemia+in+Hiroshima+and+Nagasaki%2C+1946%E2%80%931964.+I.+Distribution%2C+incidence+and+appearance+time&amp;rft.au=Bizzozero+OJ%2C+Johnson+KG%2C+Ciocco+A&amp;rft.aulast=Bizzozero+OJ%2C+Johnson+KG%2C+Ciocco+A&amp;rft.date=1966&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM196605192742001&amp;rft_id=info%3Apmid%2F5932020&amp;rft.issue=20&amp;rft.jtitle=N+Engl+J+Med&amp;rft.pages=1095-101&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=274" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-10">^</a></b></span> <span class="reference-text"><span class="citation journal">Yoshinaga S, Mabuchi K, Sigurdson AJ, Doody MM, Ron E (2004). "Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies". <i>Radiology</i> <b>233</b> (2): 313–21. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1148%2Fradiol.2332031119">10.1148/radiol.2332031119</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15375227">15375227</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Cancer+risks+among+radiologists+and+radiologic+technologists%3A+review+of+epidemiologic+studies&amp;rft.aulast=Yoshinaga+S%2C+Mabuchi+K%2C+Sigurdson+AJ%2C+Doody+MM%2C+Ron+E&amp;rft.au=Yoshinaga+S%2C+Mabuchi+K%2C+Sigurdson+AJ%2C+Doody+MM%2C+Ron+E&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1148%2Fradiol.2332031119&amp;rft_id=info%3Apmid%2F15375227&amp;rft.issue=2&amp;rft.jtitle=Radiology&amp;rft.pages=313-21&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=233" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-11">^</a></b></span> <span class="reference-text"><span class="citation book">Taylor GM, Birch JM (1996). "The hereditary basis of human leukemia". In Henderson ES, Lister TA, Greaves MF. <i>Leukemia</i> (6th ed.). Philadelphia: WB Saunders. p.&#160;210. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-7216-5381-2" title="Special:BookSources/0-7216-5381-2">0-7216-5381-2</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=The+hereditary+basis+of+human+leukemia&amp;rft.aulast=Taylor+GM%2C+Birch+JM&amp;rft.au=Taylor+GM%2C+Birch+JM&amp;rft.btitle=Leukemia&amp;rft.date=1996&amp;rft.edition=6th&amp;rft.genre=bookitem&amp;rft.isbn=0-7216-5381-2&amp;rft.pages=210&amp;rft.place=Philadelphia&amp;rft.pub=WB+Saunders&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text"><span class="citation journal">Horwitz M, Goode EL, Jarvik GP (1996). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1914843">"Anticipation in familial leukemia"</a>. <i>Am. J. Hum. Genet.</i> <b>59</b> (5): 990–8. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1914843">1914843</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8900225">8900225</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Anticipation+in+familial+leukemia&amp;rft.au=Horwitz+M%2C+Goode+EL%2C+Jarvik+GP&amp;rft.aulast=Horwitz+M%2C+Goode+EL%2C+Jarvik+GP&amp;rft.date=1996&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1914843&amp;rft_id=info%3Apmc%2F1914843&amp;rft_id=info%3Apmid%2F8900225&amp;rft.issue=5&amp;rft.jtitle=Am.+J.+Hum.+Genet.&amp;rft.pages=990-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=59" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text"><span class="citation journal">Crittenden LB (1961). "An interpretation of familial aggregation based on multiple genetic and environmental factors". <i>Ann. N. Y. Acad. Sci.</i> <b>91</b> (3): 769–80. <a href="/wiki/Bibcode" title="Bibcode">Bibcode</a>:<a rel="nofollow" class="external text" href="http://adsabs.harvard.edu/abs/1961NYASA..91..769C">1961NYASA..91..769C</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1749-6632.1961.tb31106.x">10.1111/j.1749-6632.1961.tb31106.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/13696504">13696504</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=An+interpretation+of+familial+aggregation+based+on+multiple+genetic+and+environmental+factors&amp;rft.au=Crittenden+LB&amp;rft.aulast=Crittenden+LB&amp;rft.date=1961&amp;rft.genre=article&amp;rft_id=info%3Abibcode%2F1961NYASA..91..769C&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1749-6632.1961.tb31106.x&amp;rft_id=info%3Apmid%2F13696504&amp;rft.issue=3&amp;rft.jtitle=Ann.+N.+Y.+Acad.+Sci.&amp;rft.pages=769-80&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=91" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><span class="citation journal">Horwitz M (1997). "The genetics of familial leukemia". <i>Leukemia</i> <b>11</b> (8): 1347–59. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.leu.2400707">10.1038/sj.leu.2400707</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9264391">9264391</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=The+genetics+of+familial+leukemia&amp;rft.au=Horwitz+M&amp;rft.aulast=Horwitz+M&amp;rft.date=1997&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.leu.2400707&amp;rft_id=info%3Apmid%2F9264391&amp;rft.issue=8&amp;rft.jtitle=Leukemia&amp;rft.pages=1347-59&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=11" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><span class="citation journal">Evans DI, Steward JK (1972). "Down's syndrome and leukaemia". <i>Lancet</i> <b>2</b> (7790): 1322. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0140-6736%2872%2992704-3">10.1016/S0140-6736(72)92704-3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/4117858">4117858</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Down%27s+syndrome+and+leukaemia&amp;rft.au=Evans+DI%2C+Steward+JK&amp;rft.aulast=Evans+DI%2C+Steward+JK&amp;rft.date=1972&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2872%2992704-3&amp;rft_id=info%3Apmid%2F4117858&amp;rft.issue=7790&amp;rft.jtitle=Lancet&amp;rft.pages=1322&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=2" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-16">^</a></b></span> <span class="reference-text">Abeloff, Martin et al. (2004), p. 2834.</span></li>
<li id="cite_note-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-17">^</a></b></span> <span class="reference-text"><span class="citation journal">Baldus CD, Mrózek K, Marcucci G, Bloomfield CD (June 2007). "Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review". <i>Br. J. Haematol.</i> <b>137</b> (5): 387–400. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1365-2141.2007.06566.x">10.1111/j.1365-2141.2007.06566.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17488484">17488484</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Clinical+outcome+of+de+novo+acute+myeloid+leukaemia+patients+with+normal+cytogenetics+is+affected+by+molecular+genetic+alterations%3A+a+concise+review&amp;rft.au=Baldus+CD%2C+Mr%C3%B3zek+K%2C+Marcucci+G%2C+Bloomfield+CD&amp;rft.aulast=Baldus+CD%2C+Mr%C3%B3zek+K%2C+Marcucci+G%2C+Bloomfield+CD&amp;rft.date=June+2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1365-2141.2007.06566.x&amp;rft_id=info%3Apmid%2F17488484&amp;rft.issue=5&amp;rft.jtitle=Br.+J.+Haematol.&amp;rft.pages=387-400&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=137" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Vardiman-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-Vardiman_18-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Vardiman JW, Harris NL, Brunning RD (2002). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/100/7/2292">"The World Health Organization (WHO) classification of the myeloid neoplasms"</a>. <i>Blood</i> <b>100</b> (7): 2292–302. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2002-04-1199">10.1182/blood-2002-04-1199</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12239137">12239137</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=The+World+Health+Organization+%28WHO%29+classification+of+the+myeloid+neoplasms&amp;rft.aulast=Vardiman+JW%2C+Harris+NL%2C+Brunning+RD&amp;rft.au=Vardiman+JW%2C+Harris+NL%2C+Brunning+RD&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F100%2F7%2F2292&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2002-04-1199&amp;rft_id=info%3Apmid%2F12239137&amp;rft.issue=7&amp;rft.jtitle=Blood&amp;rft.pages=2292-302&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=100" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-19">^</a></b></span> <span class="reference-text">Abeloff, Martin et al. (2004), p. 2835.</span></li>
<li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text"><span class="citation journal">Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999). "The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997". <i>Ann Oncol</i> <b>10</b> (12): 1419–32. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1023%2FA%3A1008375931236">10.1023/A:1008375931236</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10643532">10643532</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=The+World+Health+Organization+classification+of+neoplastic+diseases+of+the+hematopoietic+and+lymphoid+tissues.+Report+of+the+Clinical+Advisory+Committee+meeting%2C+Airlie+House%2C+Virginia%2C+November%2C+1997&amp;rft.au=Harris+NL%2C+Jaffe+ES%2C+Diebold+J%2C+Flandrin+G%2C+Muller-Hermelink+HK%2C+Vardiman+J%2C+Lister+TA%2C+Bloomfield+CD&amp;rft.aulast=Harris+NL%2C+Jaffe+ES%2C+Diebold+J%2C+Flandrin+G%2C+Muller-Hermelink+HK%2C+Vardiman+J%2C+Lister+TA%2C+Bloomfield+CD&amp;rft.date=1999&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1023%2FA%3A1008375931236&amp;rft_id=info%3Apmid%2F10643532&amp;rft.issue=12&amp;rft.jtitle=Ann+Oncol&amp;rft.pages=1419-32&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Amin2005-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-Amin2005_21-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Amin HM, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce SA, Kantarjian HM, O'Brien SM, Jilani I, Albitar M (2005). "Having a higher blast percentage in circulation than bone marrow: Clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias". <i>Leukemia</i> <b>19</b> (9): 1567–1572. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.leu.2403876">10.1038/sj.leu.2403876</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16049515">16049515</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Having+a+higher+blast+percentage+in+circulation+than+bone+marrow%3A+Clinical+implications+in+myelodysplastic+syndrome+and+acute+lymphoid+and+myeloid+leukemias&amp;rft.au=Amin+HM%2C+Yang+Y%2C+Shen+Y%2C+Estey+EH%2C+Giles+FJ%2C+Pierce+SA%2C+Kantarjian+HM%2C+O%27Brien+SM%2C+Jilani+I%2C+Albitar+M&amp;rft.aulast=Amin+HM%2C+Yang+Y%2C+Shen+Y%2C+Estey+EH%2C+Giles+FJ%2C+Pierce+SA%2C+Kantarjian+HM%2C+O%27Brien+SM%2C+Jilani+I%2C+Albitar+M&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.leu.2403876&amp;rft_id=info%3Apmid%2F16049515&amp;rft.issue=9&amp;rft.jtitle=Leukemia&amp;rft.pages=1567-1572&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=19" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><span class="citation journal">Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone A, Burnett A, Solomon E (1996). "Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party". <i>Br J Haematol</i> <b>94</b> (3): 557–73. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1046%2Fj.1365-2141.1996.d01-1004.x">10.1046/j.1365-2141.1996.d01-1004.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8790159">8790159</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Establishing+the+presence+of+the+t%2815%3B17%29+in+suspected+acute+promyelocytic+leukaemia%3A+cytogenetic%2C+molecular+and+PML+immunofluorescence+assessment+of+patients+entered+into+the+M.R.C.+ATRA+trial.+M.R.C.+Adult+Leukaemia+Working+Party&amp;rft.au=Grimwade+D%2C+Howe+K%2C+Langabeer+S%2C+Davies+L%2C+Oliver+F%2C+Walker+H%2C+Swirsky+D%2C+Wheatley+K%2C+Goldstone+A%2C+Burnett+A%2C+Solomon+E&amp;rft.aulast=Grimwade+D%2C+Howe+K%2C+Langabeer+S%2C+Davies+L%2C+Oliver+F%2C+Walker+H%2C+Swirsky+D%2C+Wheatley+K%2C+Goldstone+A%2C+Burnett+A%2C+Solomon+E&amp;rft.date=1996&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1046%2Fj.1365-2141.1996.d01-1004.x&amp;rft_id=info%3Apmid%2F8790159&amp;rft.issue=3&amp;rft.jtitle=Br+J+Haematol&amp;rft.pages=557-73&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=94" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><span class="citation journal">Falini B, Tiacci E, Martelli MP, Ascani S, Pileri SA (October 2010). <a rel="nofollow" class="external text" href="http://www.discoverymedicine.com/Brunangelo-Falini/2010/10/02/new-classification-of-acute-myeloid-leukemia-and-precursor-related-neoplasms-changes-and-unsolved-issues/">"New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues"</a>. <i>Discov Med</i> <b>10</b> (53): 281–92. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21034669">21034669</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=New+classification+of+acute+myeloid+leukemia+and+precursor-related+neoplasms%3A+changes+and+unsolved+issues&amp;rft.au=Falini+B%2C+Tiacci+E%2C+Martelli+MP%2C+Ascani+S%2C+Pileri+SA&amp;rft.aulast=Falini+B%2C+Tiacci+E%2C+Martelli+MP%2C+Ascani+S%2C+Pileri+SA&amp;rft.date=October++2010&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.discoverymedicine.com%2FBrunangelo-Falini%2F2010%2F10%2F02%2Fnew-classification-of-acute-myeloid-leukemia-and-precursor-related-neoplasms-changes-and-unsolved-issues%2F&amp;rft_id=info%3Apmid%2F21034669&amp;rft.issue=53&amp;rft.jtitle=Discov+Med&amp;rft.pages=281-92&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><span class="citation journal">Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1976). "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group". <i>Br J Haematol</i> <b>33</b> (4): 451–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1365-2141.1976.tb03563.x">10.1111/j.1365-2141.1976.tb03563.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/188440">188440</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Proposals+for+the+classification+of+the+acute+leukaemias.+French-American-British+%28FAB%29+co-operative+group&amp;rft.au=Bennett+JM%2C+Catovsky+D%2C+Daniel+MT%2C+Flandrin+G%2C+Galton+DA%2C+Gralnick+HR%2C+Sultan+C&amp;rft.aulast=Bennett+JM%2C+Catovsky+D%2C+Daniel+MT%2C+Flandrin+G%2C+Galton+DA%2C+Gralnick+HR%2C+Sultan+C&amp;rft.date=1976&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1365-2141.1976.tb03563.x&amp;rft_id=info%3Apmid%2F188440&amp;rft.issue=4&amp;rft.jtitle=Br+J+Haematol&amp;rft.pages=451-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=33" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-medscape-25"><span class="mw-cite-backlink">^ <a href="#cite_ref-medscape_25-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-medscape_25-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-medscape_25-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-medscape_25-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-medscape_25-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-medscape_25-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-medscape_25-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-medscape_25-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-medscape_25-8"><sup><i><b>i</b></i></sup></a></span> <span class="reference-text"><span class="citation web">Seiter, Karen; Jules, E Harris (20 May 2011). <a rel="nofollow" class="external text" href="http://emedicine.medscape.com/article/2006750-overview">"Acute Myeloid Leukemia Staging"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">26 August</span> 2011</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.aufirst=Karen&amp;rft.au=Jules%2C+E+Harris&amp;rft.aulast=Seiter&amp;rft.au=Seiter%2C+Karen&amp;rft.btitle=Acute+Myeloid+Leukemia+Staging&amp;rft.date=20+May+2011&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Femedicine.medscape.com%2Farticle%2F2006750-overview&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><span class="citation journal">Duchayne E, Demur C, Rubie H, Robert A, Dastugue N (1999). "Diagnosis of acute basophilic leukemia". <i>Leuk Lymphoma</i> <b>32</b> (3–4): 269–78. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.3109%2F10428199909167387">10.3109/10428199909167387</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10037024">10037024</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Diagnosis+of+acute+basophilic+leukemia&amp;rft.au=Duchayne+E%2C+Demur+C%2C+Rubie+H%2C+Robert+A%2C+Dastugue+N&amp;rft.aulast=Duchayne+E%2C+Demur+C%2C+Rubie+H%2C+Robert+A%2C+Dastugue+N&amp;rft.date=1999&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.3109%2F10428199909167387&amp;rft_id=info%3Apmid%2F10037024&amp;rft.issue=3%E2%80%934&amp;rft.jtitle=Leuk+Lymphoma&amp;rft.pages=269-78&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=32" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><span class="citation journal">Fialkow PJ (1976). "Clonal origin of human tumors". <i>Biochim. Biophys. Acta</i> <b>458</b> (3): 283–321. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2F0304-419X%2876%2990003-2">10.1016/0304-419X(76)90003-2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/1067873">1067873</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Clonal+origin+of+human+tumors&amp;rft.au=Fialkow+PJ&amp;rft.aulast=Fialkow+PJ&amp;rft.date=1976&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2F0304-419X%2876%2990003-2&amp;rft_id=info%3Apmid%2F1067873&amp;rft.issue=3&amp;rft.jtitle=Biochim.+Biophys.+Acta&amp;rft.pages=283-321&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=458" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><span class="citation journal">Fialkow PJ, Janssen JW, Bartram CR (1 April 1991). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/reprint/77/7/1415">"Clonal remissions in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancy"</a> <span style="font-size:85%;">(PDF)</span>. <i>Blood</i> <b>77</b> (7): 1415–7. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2009365">2009365</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Clonal+remissions+in+acute+nonlymphocytic+leukemia%3A+evidence+for+a+multistep+pathogenesis+of+the+malignancy&amp;rft.au=Fialkow+PJ%2C+Janssen+JW%2C+Bartram+CR&amp;rft.aulast=Fialkow+PJ%2C+Janssen+JW%2C+Bartram+CR&amp;rft.date=1+April+1991&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Freprint%2F77%2F7%2F1415&amp;rft_id=info%3Apmid%2F2009365&amp;rft.issue=7&amp;rft.jtitle=Blood&amp;rft.pages=1415-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=77" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><span class="citation journal">Bonnet D, Dick JE (1997). "Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell". <i>Nat. Med.</i> <b>3</b> (7): 730–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnm0797-730">10.1038/nm0797-730</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9212098">9212098</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Human+acute+myeloid+leukemia+is+organized+as+a+hierarchy+that+originates+from+a+primitive+hematopoietic+cell&amp;rft.au=Bonnet+D%2C+Dick+JE&amp;rft.aulast=Bonnet+D%2C+Dick+JE&amp;rft.date=1997&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fnm0797-730&amp;rft_id=info%3Apmid%2F9212098&amp;rft.issue=7&amp;rft.jtitle=Nat.+Med.&amp;rft.pages=730-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=3" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text">Abeloff, Martin et al. (2004), pp. 2831–32.</span></li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><span class="citation book">Greer JP et al., eds. (2004). <i>Wintrobe's Clinical Hematology</i> (11th ed.). Philadelphia: Lippincott, Williams, and Wilkins. pp.&#160;2045–2062. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-7817-3650-1" title="Special:BookSources/0-7817-3650-1">0-7817-3650-1</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.btitle=Wintrobe%27s+Clinical+Hematology&amp;rft.date=2004&amp;rft.edition=11th&amp;rft.genre=book&amp;rft.isbn=0-7817-3650-1&amp;rft.pages=2045-2062&amp;rft.place=Philadelphia&amp;rft.pub=Lippincott%2C+Williams%2C+and+Wilkins&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text"><span class="citation journal">Melnick A, Licht JD (15 May 1999). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/93/10/3167">"Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia"</a>. <i>Blood</i> <b>93</b> (10): 3167–215. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10233871">10233871</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Deconstructing+a+disease%3A+RAR%CE%B1%2C+its+fusion+partners%2C+and+their+roles+in+the+pathogenesis+of+acute+promyelocytic+leukemia&amp;rft.aulast=Melnick+A%2C+Licht+JD&amp;rft.au=Melnick+A%2C+Licht+JD&amp;rft.date=15+May+1999&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F93%2F10%2F3167&amp;rft_id=info%3Apmid%2F10233871&amp;rft.issue=10&amp;rft.jtitle=Blood&amp;rft.pages=3167-215&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=93" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text">Abeloff, Martin et al. (2004), p. 2828.</span></li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.mountsinai.org/patient-care/health-library/diseases-and-conditions/acute-myelogenous-leukemia-adult">Acute myeloid leukemia</a> at <a href="/wiki/Mount_Sinai_Hospital,_New_York" title="Mount Sinai Hospital, New York" class="mw-redirect">Mount Sinai Hospital</a></span></li>
<li id="cite_note-treatment-35"><span class="mw-cite-backlink">^ <a href="#cite_ref-treatment_35-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-treatment_35-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Abeloff, Martin et al. (2004), pp. 2835–39.</span></li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text"><span class="citation journal">Bishop JF (1997). "The treatment of adult acute myeloid leukemia". <i>Semin Oncol</i> <b>24</b> (1): 57–69. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9045305">9045305</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=The+treatment+of+adult+acute+myeloid+leukemia&amp;rft.au=Bishop+JF&amp;rft.aulast=Bishop+JF&amp;rft.date=1997&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F9045305&amp;rft.issue=1&amp;rft.jtitle=Semin+Oncol&amp;rft.pages=57-69&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=24" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text"><span class="citation journal">Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M (15 October 1996). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/reprint/88/8/2841">"A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study"</a>. <i>Blood</i> <b>88</b> (8): 2841–51. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8874180">8874180</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=A+randomized+investigation+of+high-dose+versus+standard-dose+cytosine+arabinoside+with+daunorubicin+in+patients+with+previously+untreated+acute+myeloid+leukemia%3A+a+Southwest+Oncology+Group+study&amp;rft.aulast=Weick+JK%2C+Kopecky+KJ%2C+Appelbaum+FR%2C+Head+DR%2C+Kingsbury+LL%2C+Balcerzak+SP%2C+Bickers+JN%2C+Hynes+HE%2C+Welborn+JL%2C+Simon+SR%2C+Grever+M&amp;rft.au=Weick+JK%2C+Kopecky+KJ%2C+Appelbaum+FR%2C+Head+DR%2C+Kingsbury+LL%2C+Balcerzak+SP%2C+Bickers+JN%2C+Hynes+HE%2C+Welborn+JL%2C+Simon+SR%2C+Grever+M&amp;rft.date=15+October+1996&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Freprint%2F88%2F8%2F2841&amp;rft_id=info%3Apmid%2F8874180&amp;rft.issue=8&amp;rft.jtitle=Blood&amp;rft.pages=2841-51&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=88" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-38">^</a></b></span> <span class="reference-text"><span class="citation journal">Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S (1 March 1996). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/reprint/87/5/1710">"A randomized study of high-dose cytarabine in induction in acute myeloid leukemia"</a>. <i>Blood</i> <b>87</b> (5): 1710–7. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8634416">8634416</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=A+randomized+study+of+high-dose+cytarabine+in+induction+in+acute+myeloid+leukemia&amp;rft.au=Bishop+JF%2C+Matthews+JP%2C+Young+GA%2C+Szer+J%2C+Gillett+A%2C+Joshua+D%2C+Bradstock+K%2C+Enno+A%2C+Wolf+MM%2C+Fox+R%2C+Cobcroft+R%2C+Herrmann+R%2C+Van+Der+Weyden+M%2C+Lowenthal+RM%2C+Page+F%2C+Garson+OM%2C+Juneja+S&amp;rft.aulast=Bishop+JF%2C+Matthews+JP%2C+Young+GA%2C+Szer+J%2C+Gillett+A%2C+Joshua+D%2C+Bradstock+K%2C+Enno+A%2C+Wolf+MM%2C+Fox+R%2C+Cobcroft+R%2C+Herrmann+R%2C+Van+Der+Weyden+M%2C+Lowenthal+RM%2C+Page+F%2C+Garson+OM%2C+Juneja+S&amp;rft.date=1+March+1996&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Freprint%2F87%2F5%2F1710&amp;rft_id=info%3Apmid%2F8634416&amp;rft.issue=5&amp;rft.jtitle=Blood&amp;rft.pages=1710-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=87" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><span class="citation journal">Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY (1 August 1988). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/reprint/72/2/567">"Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia"</a>. <i>Blood</i> <b>72</b> (2): 567–72. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3165295">3165295</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Use+of+all-trans+retinoic+acid+in+the+treatment+of+acute+promyelocytic+leukemia&amp;rft.au=Huang+ME%2C+Ye+YC%2C+Chen+SR%2C+Chai+JR%2C+Lu+JX%2C+Zhoa+L%2C+Gu+LJ%2C+Wang+ZY&amp;rft.aulast=Huang+ME%2C+Ye+YC%2C+Chen+SR%2C+Chai+JR%2C+Lu+JX%2C+Zhoa+L%2C+Gu+LJ%2C+Wang+ZY&amp;rft.date=1+August+1988&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Freprint%2F72%2F2%2F567&amp;rft_id=info%3Apmid%2F3165295&amp;rft.issue=2&amp;rft.jtitle=Blood&amp;rft.pages=567-72&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=72" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-40">^</a></b></span> <span class="reference-text"><span class="citation journal">Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH (1997). <a rel="nofollow" class="external text" href="http://content.nejm.org/cgi/content/full/337/15/1021">"All-trans-retinoic acid in acute promyelocytic leukemia"</a>. <i>N. Engl. J. Med.</i> <b>337</b> (15): 1021–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJM199710093371501">10.1056/NEJM199710093371501</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9321529">9321529</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=All-trans-retinoic+acid+in+acute+promyelocytic+leukemia&amp;rft.aulast=Tallman+MS%2C+Andersen+JW%2C+Schiffer+CA%2C+Appelbaum+FR%2C+Feusner+JH%2C+Ogden+A%2C+Shepherd+L%2C+Willman+C%2C+Bloomfield+CD%2C+Rowe+JM%2C+Wiernik+PH&amp;rft.au=Tallman+MS%2C+Andersen+JW%2C+Schiffer+CA%2C+Appelbaum+FR%2C+Feusner+JH%2C+Ogden+A%2C+Shepherd+L%2C+Willman+C%2C+Bloomfield+CD%2C+Rowe+JM%2C+Wiernik+PH&amp;rft.date=1997&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fcontent.nejm.org%2Fcgi%2Fcontent%2Ffull%2F337%2F15%2F1021&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM199710093371501&amp;rft_id=info%3Apmid%2F9321529&amp;rft.issue=15&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=1021-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=337" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text"><span class="citation journal">Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L (15 August 1999). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/94/4/1192">"A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group"</a>. <i>Blood</i> <b>94</b> (4): 1192–200. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10438706">10438706</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=A+randomized+comparison+of+all+transretinoic+acid+%28ATRA%29+followed+by+chemotherapy+and+ATRA+plus+chemotherapy+and+the+role+of+maintenance+therapy+in+newly+diagnosed+acute+promyelocytic+leukemia.+The+European+APL+Group&amp;rft.au=Fenaux+P%2C+Chastang+C%2C+Chevret+S%2C+Sanz+M%2C+Dombret+H%2C+Archimbaud+E%2C+Fey+M%2C+Rayon+C%2C+Huguet+F%2C+Sotto+JJ%2C+Gardin+C%2C+Makhoul+PC%2C+Travade+P%2C+Solary+E%2C+Fegueux+N%2C+Bordessoule+D%2C+Miguel+JS%2C+Link+H%2C+Desablens+B%2C+Stamatoullas+A%2C+Deconinck+E%2C+Maloisel+F%2C+Castaigne+S%2C+Preudhomme+C%2C+Degos+L&amp;rft.aulast=Fenaux+P%2C+Chastang+C%2C+Chevret+S%2C+Sanz+M%2C+Dombret+H%2C+Archimbaud+E%2C+Fey+M%2C+Rayon+C%2C+Huguet+F%2C+Sotto+JJ%2C+Gardin+C%2C+Makhoul+PC%2C+Travade+P%2C+Solary+E%2C+Fegueux+N%2C+Bordessoule+D%2C+Miguel+JS%2C+Link+H%2C+Desablens+B%2C+Stamatoullas+A%2C+Deconinck+E%2C+Maloisel+F%2C+Castaigne+S%2C+Preudhomme+C%2C+Degos+L&amp;rft.date=15+August+1999&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F94%2F4%2F1192&amp;rft_id=info%3Apmid%2F10438706&amp;rft.issue=4&amp;rft.jtitle=Blood&amp;rft.pages=1192-200&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=94" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><span class="citation journal">Estey EH (2002). "Treatment of acute myelogenous leukemia". <i>Oncology (Williston Park)</i> <b>16</b> (3): 343–52, 355–6; discussion 357, 362, 365–6. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15046392">15046392</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Treatment+of+acute+myelogenous+leukemia&amp;rft.au=Estey+EH&amp;rft.aulast=Estey+EH&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F15046392&amp;rft.issue=3&amp;rft.jtitle=Oncology+%28Williston+Park%29&amp;rft.pages=343-52%2C+355-6%3B+discussion+357%2C+362%2C+365-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=16" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-43">^</a></b></span> <span class="reference-text"><span class="citation journal">Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, Bennett JM, O'Connell MJ (1988). "Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia". <i>J Clin Oncol</i> <b>6</b> (4): 583–7. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3282032">3282032</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Maintenance+chemotherapy+prolongs+remission+duration+in+adult+acute+nonlymphocytic+leukemia&amp;rft.au=Cassileth+PA%2C+Harrington+DP%2C+Hines+JD%2C+Oken+MM%2C+Mazza+JJ%2C+McGlave+P%2C+Bennett+JM%2C+O%27Connell+MJ&amp;rft.aulast=Cassileth+PA%2C+Harrington+DP%2C+Hines+JD%2C+Oken+MM%2C+Mazza+JJ%2C+McGlave+P%2C+Bennett+JM%2C+O%27Connell+MJ&amp;rft.date=1988&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F3282032&amp;rft.issue=4&amp;rft.jtitle=J+Clin+Oncol&amp;rft.pages=583-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=6" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-44">^</a></b></span> <span class="reference-text"><span class="citation journal">Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, Bennett JM, O'Connell MJ (1988). "Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia". <i>J. Clin. Oncol.</i> <b>6</b> (4): 583–7. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3282032">3282032</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Maintenance+chemotherapy+prolongs+remission+duration+in+adult+acute+nonlymphocytic+leukemia&amp;rft.au=Cassileth+PA%2C+Harrington+DP%2C+Hines+JD%2C+Oken+MM%2C+Mazza+JJ%2C+McGlave+P%2C+Bennett+JM%2C+O%27Connell+MJ&amp;rft.aulast=Cassileth+PA%2C+Harrington+DP%2C+Hines+JD%2C+Oken+MM%2C+Mazza+JJ%2C+McGlave+P%2C+Bennett+JM%2C+O%27Connell+MJ&amp;rft.date=1988&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F3282032&amp;rft.issue=4&amp;rft.jtitle=J.+Clin.+Oncol.&amp;rft.pages=583-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=6" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text"><span class="citation journal">Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E (1994). "Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B". <i>N. Engl. J. Med.</i> <b>331</b> (14): 896–903. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJM199410063311402">10.1056/NEJM199410063311402</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8078551">8078551</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Intensive+postremission+chemotherapy+in+adults+with+acute+myeloid+leukemia.+Cancer+and+Leukemia+Group+B&amp;rft.aulast=Mayer+RJ%2C+Davis+RB%2C+Schiffer+CA%2C+Berg+DT%2C+Powell+BL%2C+Schulman+P%2C+Omura+GA%2C+Moore+JO%2C+McIntyre+OR%2C+Frei+E&amp;rft.au=Mayer+RJ%2C+Davis+RB%2C+Schiffer+CA%2C+Berg+DT%2C+Powell+BL%2C+Schulman+P%2C+Omura+GA%2C+Moore+JO%2C+McIntyre+OR%2C+Frei+E&amp;rft.date=1994&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM199410063311402&amp;rft_id=info%3Apmid%2F8078551&amp;rft.issue=14&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=896-903&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=331" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-nccn-46"><span class="mw-cite-backlink">^ <a href="#cite_ref-nccn_46-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-nccn_46-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Appelbaum FR, Baer MR, Carabasi MH, Coutre SE, Erba HP, Estey E, Glenn MJ, Kraut EH, Maslak P, Millenson M, Miller CB, Saba HI, Stone R, Tallman MS (2000). "NCCN Practice Guidelines for Acute Myelogenous Leukemia". <i>Oncology (Williston Park, N.Y.)</i> <b>14</b> (11A): 53–61. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11195419">11195419</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=NCCN+Practice+Guidelines+for+Acute+Myelogenous+Leukemia&amp;rft.au=Appelbaum+FR%2C+Baer+MR%2C+Carabasi+MH%2C+Coutre+SE%2C+Erba+HP%2C+Estey+E%2C+Glenn+MJ%2C+Kraut+EH%2C+Maslak+P%2C+Millenson+M%2C+Miller+CB%2C+Saba+HI%2C+Stone+R%2C+Tallman+MS&amp;rft.aulast=Appelbaum+FR%2C+Baer+MR%2C+Carabasi+MH%2C+Coutre+SE%2C+Erba+HP%2C+Estey+E%2C+Glenn+MJ%2C+Kraut+EH%2C+Maslak+P%2C+Millenson+M%2C+Miller+CB%2C+Saba+HI%2C+Stone+R%2C+Tallman+MS&amp;rft.date=2000&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F11195419&amp;rft.issue=11A&amp;rft.jtitle=Oncology+%28Williston+Park%2C+N.Y.%29&amp;rft.pages=53-61&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=14" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text"><span class="citation journal">Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, Wallhult E, Hellstrand K (July 2006). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/108/1/88">"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial"</a>. <i>Blood</i> <b>108</b> (1): 88–96. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2005-10-4073">10.1182/blood-2005-10-4073</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16556892">16556892</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Improved+leukemia-free+survival+after+postconsolidation+immunotherapy+with+histamine+dihydrochloride+and+interleukin-2+in+acute+myeloid+leukemia%3A+results+of+a+randomized+phase+3+trial&amp;rft.au=Brune+M%2C+Castaigne+S%2C+Catalano+J%2C+Gehlsen+K%2C+Ho+AD%2C+Hofmann+WK%2C+Hogge+DE%2C+Nilsson+B%2C+Or+R%2C+Romero+AI%2C+Rowe+JM%2C+Simonsson+B%2C+Spearing+R%2C+Stadtmauer+EA%2C+Szer+J%2C+Wallhult+E%2C+Hellstrand+K&amp;rft.aulast=Brune+M%2C+Castaigne+S%2C+Catalano+J%2C+Gehlsen+K%2C+Ho+AD%2C+Hofmann+WK%2C+Hogge+DE%2C+Nilsson+B%2C+Or+R%2C+Romero+AI%2C+Rowe+JM%2C+Simonsson+B%2C+Spearing+R%2C+Stadtmauer+EA%2C+Szer+J%2C+Wallhult+E%2C+Hellstrand+K&amp;rft.date=July+2006&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F108%2F1%2F88&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2005-10-4073&amp;rft_id=info%3Apmid%2F16556892&amp;rft.issue=1&amp;rft.jtitle=Blood&amp;rft.pages=88-96&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=108" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-relapse-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-relapse_48-0">^</a></b></span> <span class="reference-text">Abeloff, Martin et al. (2004), pp. 2840–41.</span></li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><span class="citation journal">Appelbaum FR (2001). "Editorial: Who should be transplanted for AML?". <i>Leukemia</i> <b>15</b> (4): 680–2. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj%2Fleu%2F2402074">10.1038/sj/leu/2402074</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11368380">11368380</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Editorial%3A+Who+should+be+transplanted+for+AML%3F&amp;rft.au=Appelbaum+FR&amp;rft.aulast=Appelbaum+FR&amp;rft.date=2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj%2Fleu%2F2402074&amp;rft_id=info%3Apmid%2F11368380&amp;rft.issue=4&amp;rft.jtitle=Leukemia&amp;rft.pages=680-2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=15" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-50">^</a></b></span> <span class="reference-text"><span class="citation journal">Appelbaum FR (2002). <a rel="nofollow" class="external text" href="http://www.nature.com/leu/journal/v16/n2/full/2402345a.html">"Keynote address: hematopoietic cell transplantation beyond first remission"</a>. <i>Leukemia</i> <b>16</b> (2): 157–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.leu.2402345">10.1038/sj.leu.2402345</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11840278">11840278</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Keynote+address%3A+hematopoietic+cell+transplantation+beyond+first+remission&amp;rft.au=Appelbaum+FR&amp;rft.aulast=Appelbaum+FR&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fleu%2Fjournal%2Fv16%2Fn2%2Ffull%2F2402345a.html&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.leu.2402345&amp;rft_id=info%3Apmid%2F11840278&amp;rft.issue=2&amp;rft.jtitle=Leukemia&amp;rft.pages=157-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=16" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-51">^</a></b></span> <span class="reference-text"><span class="citation journal">Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR (1 July 2001). <a rel="nofollow" class="external text" href="http://jco.ascopubs.org/cgi/content/full/19/13/3244">"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse"</a>. <i>J. Clin. Oncol.</i> <b>19</b> (13): 3244–54. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11432892">11432892</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Efficacy+and+safety+of+gemtuzumab+ozogamicin+in+patients+with+CD33-positive+acute+myeloid+leukemia+in+first+relapse&amp;rft.aulast=Sievers+EL%2C+Larson+RA%2C+Stadtmauer+EA%2C+Estey+E%2C+L%C3%B6wenberg+B%2C+Dombret+H%2C+Karanes+C%2C+Theobald+M%2C+Bennett+JM%2C+Sherman+ML%2C+Berger+MS%2C+Eten+CB%2C+Loken+MR%2C+van+Dongen+JJ%2C+Bernstein+ID%2C+Appelbaum+FR&amp;rft.au=Sievers+EL%2C+Larson+RA%2C+Stadtmauer+EA%2C+Estey+E%2C+L%C3%B6wenberg+B%2C+Dombret+H%2C+Karanes+C%2C+Theobald+M%2C+Bennett+JM%2C+Sherman+ML%2C+Berger+MS%2C+Eten+CB%2C+Loken+MR%2C+van+Dongen+JJ%2C+Bernstein+ID%2C+Appelbaum+FR&amp;rft.date=1+July+2001&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Ffull%2F19%2F13%2F3244&amp;rft_id=info%3Apmid%2F11432892&amp;rft.issue=13&amp;rft.jtitle=J.+Clin.+Oncol.&amp;rft.pages=3244-54&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=19" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="http://www.pfizer.com/files/products/mylotarg_hcp_letter.pdf">http://www.pfizer.com/files/products/mylotarg_hcp_letter.pdf</a></span></li>
<li id="cite_note-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-53">^</a></b></span> <span class="reference-text"><span class="citation journal">Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP (15 September 2001). <a rel="nofollow" class="external text" href="http://jco.ascopubs.org/cgi/content/full/19/18/3852">"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia"</a>. <i>J. Clin. Oncol.</i> <b>19</b> (18): 3852–60. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11559723">11559723</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=United+States+multicenter+study+of+arsenic+trioxide+in+relapsed+acute+promyelocytic+leukemia&amp;rft.aulast=Soignet+SL%2C+Frankel+SR%2C+Douer+D%2C+Tallman+MS%2C+Kantarjian+H%2C+Calleja+E%2C+Stone+RM%2C+Kalaycio+M%2C+Scheinberg+DA%2C+Steinherz+P%2C+Sievers+EL%2C+Coutr%C3%A9+S%2C+Dahlberg+S%2C+Ellison+R%2C+Warrell+RP&amp;rft.au=Soignet+SL%2C+Frankel+SR%2C+Douer+D%2C+Tallman+MS%2C+Kantarjian+H%2C+Calleja+E%2C+Stone+RM%2C+Kalaycio+M%2C+Scheinberg+DA%2C+Steinherz+P%2C+Sievers+EL%2C+Coutr%C3%A9+S%2C+Dahlberg+S%2C+Ellison+R%2C+Warrell+RP&amp;rft.date=15+September+2001&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Ffull%2F19%2F18%2F3852&amp;rft_id=info%3Apmid%2F11559723&amp;rft.issue=18&amp;rft.jtitle=J.+Clin.+Oncol.&amp;rft.pages=3852-60&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=19" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-prog-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-prog_54-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Estey EH (2001). "Prognostic factors in acute myelogenous leukemia". <i>Leukemia</i> <b>15</b> (4): 670–2. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj%2Fleu%2F2402057">10.1038/sj/leu/2402057</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11368376">11368376</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Prognostic+factors+in+acute+myelogenous+leukemia&amp;rft.au=Estey+EH&amp;rft.aulast=Estey+EH&amp;rft.date=2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj%2Fleu%2F2402057&amp;rft_id=info%3Apmid%2F11368376&amp;rft.issue=4&amp;rft.jtitle=Leukemia&amp;rft.pages=670-2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=15" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-55">^</a></b></span> <span class="reference-text"><span class="citation journal">Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JK, Stevens RF, Walker H (1999). "A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties". <i>Br J Haematol</i> <b>107</b> (1): 69–79. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1046%2Fj.1365-2141.1999.01684.x">10.1046/j.1365-2141.1999.01684.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10520026">10520026</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=A+simple%2C+robust%2C+validated+and+highly+predictive+index+for+the+determination+of+risk-directed+therapy+in+acute+myeloid+leukaemia+derived+from+the+MRC+AML+10+trial.+United+Kingdom+Medical+Research+Council%27s+Adult+and+Childhood+Leukaemia+Working+Parties&amp;rft.aulast=Wheatley+K%2C+Burnett+AK%2C+Goldstone+AH%2C+Gray+RG%2C+Hann+IM%2C+Harrison+CJ%2C+Rees+JK%2C+Stevens+RF%2C+Walker+H&amp;rft.au=Wheatley+K%2C+Burnett+AK%2C+Goldstone+AH%2C+Gray+RG%2C+Hann+IM%2C+Harrison+CJ%2C+Rees+JK%2C+Stevens+RF%2C+Walker+H&amp;rft.date=1999&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1046%2Fj.1365-2141.1999.01684.x&amp;rft_id=info%3Apmid%2F10520026&amp;rft.issue=1&amp;rft.jtitle=Br+J+Haematol&amp;rft.pages=69-79&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=107" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-56">^</a></b></span> <span class="reference-text"><span class="citation journal">Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR (15 December 2000). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/96/13/4075">"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study"</a>. <i>Blood</i> <b>96</b> (13): 4075–83. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11110676">11110676</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Karyotypic+analysis+predicts+outcome+of+preremission+and+postremission+therapy+in+adult+acute+myeloid+leukemia%3A+a+Southwest+Oncology+Group%2FEastern+Cooperative+Oncology+Group+Study&amp;rft.aulast=Slovak+ML%2C+Kopecky+KJ%2C+Cassileth+PA%2C+Harrington+DH%2C+Theil+KS%2C+Mohamed+A%2C+Paietta+E%2C+Willman+CL%2C+Head+DR%2C+Rowe+JM%2C+Forman+SJ%2C+Appelbaum+FR&amp;rft.au=Slovak+ML%2C+Kopecky+KJ%2C+Cassileth+PA%2C+Harrington+DH%2C+Theil+KS%2C+Mohamed+A%2C+Paietta+E%2C+Willman+CL%2C+Head+DR%2C+Rowe+JM%2C+Forman+SJ%2C+Appelbaum+FR&amp;rft.date=15+December+2000&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F96%2F13%2F4075&amp;rft_id=info%3Apmid%2F11110676&amp;rft.issue=13&amp;rft.jtitle=Blood&amp;rft.pages=4075-83&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=96" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-57"><span class="mw-cite-backlink"><b><a href="#cite_ref-57">^</a></b></span> <span class="reference-text"><span class="citation journal">Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD (2002). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/100/13/4325">"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)"</a>. <i>Blood</i> <b>100</b> (13): 4325–36. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2002-03-0772">10.1182/blood-2002-03-0772</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12393746">12393746</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Pretreatment+cytogenetic+abnormalities+are+predictive+of+induction+success%2C+cumulative+incidence+of+relapse%2C+and+overall+survival+in+adult+patients+with+de+novo+acute+myeloid+leukemia%3A+results+from+Cancer+and+Leukemia+Group+B+%28CALGB+8461%29&amp;rft.au=Byrd+JC%2C+Mr%C3%B3zek+K%2C+Dodge+RK%2C+Carroll+AJ%2C+Edwards+CG%2C+Arthur+DC%2C+Pettenati+MJ%2C+Patil+SR%2C+Rao+KW%2C+Watson+MS%2C+Koduru+PR%2C+Moore+JO%2C+Stone+RM%2C+Mayer+RJ%2C+Feldman+EJ%2C+Davey+FR%2C+Schiffer+CA%2C+Larson+RA%2C+Bloomfield+CD&amp;rft.aulast=Byrd+JC%2C+Mr%C3%B3zek+K%2C+Dodge+RK%2C+Carroll+AJ%2C+Edwards+CG%2C+Arthur+DC%2C+Pettenati+MJ%2C+Patil+SR%2C+Rao+KW%2C+Watson+MS%2C+Koduru+PR%2C+Moore+JO%2C+Stone+RM%2C+Mayer+RJ%2C+Feldman+EJ%2C+Davey+FR%2C+Schiffer+CA%2C+Larson+RA%2C+Bloomfield+CD&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F100%2F13%2F4325&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2002-03-0772&amp;rft_id=info%3Apmid%2F12393746&amp;rft.issue=13&amp;rft.jtitle=Blood&amp;rft.pages=4325-36&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=100" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-58">^</a></b></span> <span class="reference-text"><span class="citation journal">Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1 October 1998). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/92/7/2322">"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties"</a>. <i>Blood</i> <b>92</b> (7): 2322–33. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9746770">9746770</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=The+importance+of+diagnostic+cytogenetics+on+outcome+in+AML%3A+analysis+of+1%2C612+patients+entered+into+the+MRC+AML+10+trial.+The+Medical+Research+Council+Adult+and+Children%27s+Leukaemia+Working+Parties&amp;rft.au=Grimwade+D%2C+Walker+H%2C+Oliver+F%2C+Wheatley+K%2C+Harrison+C%2C+Harrison+G%2C+Rees+J%2C+Hann+I%2C+Stevens+R%2C+Burnett+A%2C+Goldstone+A&amp;rft.aulast=Grimwade+D%2C+Walker+H%2C+Oliver+F%2C+Wheatley+K%2C+Harrison+C%2C+Harrison+G%2C+Rees+J%2C+Hann+I%2C+Stevens+R%2C+Burnett+A%2C+Goldstone+A&amp;rft.date=1+October+1998&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F92%2F7%2F2322&amp;rft_id=info%3Apmid%2F9746770&amp;rft.issue=7&amp;rft.jtitle=Blood&amp;rft.pages=2322-33&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=92" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-59">^</a></b></span> <span class="reference-text"><span class="citation journal">Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR (2000). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/92/7/2322">"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study"</a>. <i>Blood</i> <b>96</b> (13): 4075–83. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11110676">11110676</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Karyotypic+analysis+predicts+outcome+of+preremission+and+postremission+therapy+in+adult+acute+myeloid+leukemia%3A+a+Southwest+Oncology+Group%2FEastern+Cooperative+Oncology+Group+Study&amp;rft.aulast=Slovak+ML%2C+Kopecky+KJ%2C+Cassileth+PA%2C+Harrington+DH%2C+Theil+KS%2C+Mohamed+A%2C+Paietta+E%2C+Willman+CL%2C+Head+DR%2C+Rowe+JM%2C+Forman+SJ%2C+Appelbaum+FR&amp;rft.au=Slovak+ML%2C+Kopecky+KJ%2C+Cassileth+PA%2C+Harrington+DH%2C+Theil+KS%2C+Mohamed+A%2C+Paietta+E%2C+Willman+CL%2C+Head+DR%2C+Rowe+JM%2C+Forman+SJ%2C+Appelbaum+FR&amp;rft.date=2000&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F92%2F7%2F2322&amp;rft_id=info%3Apmid%2F11110676&amp;rft.issue=13&amp;rft.jtitle=Blood&amp;rft.pages=4075-83&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=96" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-60"><span class="mw-cite-backlink"><b><a href="#cite_ref-60">^</a></b></span> <span class="reference-text"><span class="citation journal">Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD (2002). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/100/13/4325">"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)"</a>. <i>Blood</i> <b>100</b> (13): 4325–36. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2002-03-0772">10.1182/blood-2002-03-0772</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12393746">12393746</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Pretreatment+cytogenetic+abnormalities+are+predictive+of+induction+success%2C+cumulative+incidence+of+relapse%2C+and+overall+survival+in+adult+patients+with+de+novo+acute+myeloid+leukemia%3A+results+from+Cancer+and+Leukemia+Group+B+%28CALGB+8461%29&amp;rft.au=Byrd+JC%2C+Mr%C3%B3zek+K%2C+Dodge+RK%2C+Carroll+AJ%2C+Edwards+CG%2C+Arthur+DC%2C+Pettenati+MJ%2C+Patil+SR%2C+Rao+KW%2C+Watson+MS%2C+Koduru+PR%2C+Moore+JO%2C+Stone+RM%2C+Mayer+RJ%2C+Feldman+EJ%2C+Davey+FR%2C+Schiffer+CA%2C+Larson+RA%2C+Bloomfield+CD&amp;rft.aulast=Byrd+JC%2C+Mr%C3%B3zek+K%2C+Dodge+RK%2C+Carroll+AJ%2C+Edwards+CG%2C+Arthur+DC%2C+Pettenati+MJ%2C+Patil+SR%2C+Rao+KW%2C+Watson+MS%2C+Koduru+PR%2C+Moore+JO%2C+Stone+RM%2C+Mayer+RJ%2C+Feldman+EJ%2C+Davey+FR%2C+Schiffer+CA%2C+Larson+RA%2C+Bloomfield+CD&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F100%2F13%2F4325&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2002-03-0772&amp;rft_id=info%3Apmid%2F12393746&amp;rft.issue=13&amp;rft.jtitle=Blood&amp;rft.pages=4325-36&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=100" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-61">^</a></b></span> <span class="reference-text"><span class="citation journal">Thirman MJ, Larson RA (1996). "Therapy-related myeloid leukemia". <i>Hematol Oncol Clin North Am</i> <b>10</b> (2): 293–320. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0889-8588%2805%2970340-3">10.1016/S0889-8588(05)70340-3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8707757">8707757</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Therapy-related+myeloid+leukemia&amp;rft.aulast=Thirman+MJ%2C+Larson+RA&amp;rft.au=Thirman+MJ%2C+Larson+RA&amp;rft.date=1996&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0889-8588%2805%2970340-3&amp;rft_id=info%3Apmid%2F8707757&amp;rft.issue=2&amp;rft.jtitle=Hematol+Oncol+Clin+North+Am&amp;rft.pages=293-320&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-62"><span class="mw-cite-backlink"><b><a href="#cite_ref-62">^</a></b></span> <span class="reference-text"><span class="citation journal">Rowley JD, Golomb HM, Vardiman JW (1 October 1981). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/58/4/759">"Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease"</a>. <i>Blood</i> <b>58</b> (4): 759–67. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7272506">7272506</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Nonrandom+chromosome+abnormalities+in+acute+leukemia+and+dysmyelopoietic+syndromes+in+patients+with+previously+treated+malignant+disease&amp;rft.aulast=Rowley+JD%2C+Golomb+HM%2C+Vardiman+JW&amp;rft.au=Rowley+JD%2C+Golomb+HM%2C+Vardiman+JW&amp;rft.date=1+October+1981&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F58%2F4%2F759&amp;rft_id=info%3Apmid%2F7272506&amp;rft.issue=4&amp;rft.jtitle=Blood&amp;rft.pages=759-67&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=58" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-63"><span class="mw-cite-backlink"><b><a href="#cite_ref-63">^</a></b></span> <span class="reference-text"><span class="citation journal">Lee JT, Lee JD, Choe KO, Yang WI (2002). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/99/6/1909">"Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia"</a>. <i>Blood</i> <b>99</b> (6): 1909–12. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood.V99.6.1909">10.1182/blood.V99.6.1909</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/1877259">1877259</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Genetic+pathways+in+therapy-related+myelodysplasia+and+acute+myeloid+leukemia&amp;rft.aulast=Lee+JT%2C+Lee+JD%2C+Choe+KO%2C+Yang+WI&amp;rft.au=Lee+JT%2C+Lee+JD%2C+Choe+KO%2C+Yang+WI&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F99%2F6%2F1909&amp;rft_id=info%3Adoi%2F10.1182%2Fblood.V99.6.1909&amp;rft_id=info%3Apmid%2F1877259&amp;rft.issue=6&amp;rft.jtitle=Blood&amp;rft.pages=1909-12&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=99" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-64"><span class="mw-cite-backlink"><b><a href="#cite_ref-64">^</a></b></span> <span class="reference-text"><span class="citation journal">Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W (2003). <a rel="nofollow" class="external text" href="http://jco.ascopubs.org/cgi/content/full/21/2/256">"Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies"</a>. <i>J. Clin. Oncol.</i> <b>21</b> (2): 256–65. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1200%2FJCO.2003.08.005">10.1200/JCO.2003.08.005</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12525517">12525517</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Morphologic+dysplasia+in+de+novo+acute+myeloid+leukemia+%28AML%29+is+related+to+unfavorable+cytogenetics+but+has+no+independent+prognostic+relevance+under+the+conditions+of+intensive+induction+therapy%3A+results+of+a+multiparameter+analysis+from+the+German+AML+Cooperative+Group+studies&amp;rft.au=Haferlach+T%2C+Schoch+C%2C+L%C3%B6ffler+H%2C+Gassmann+W%2C+Kern+W%2C+Schnittger+S%2C+Fonatsch+C%2C+Ludwig+WD%2C+Wuchter+C%2C+Schlegelberger+B%2C+Staib+P%2C+Reichle+A%2C+Kubica+U%2C+Eimermacher+H%2C+Balleisen+L%2C+Gr%C3%BCneisen+A%2C+Haase+D%2C+Aul+C%2C+Karow+J%2C+Lengfelder+E%2C+W%C3%B6rmann+B%2C+Heinecke+A%2C+Sauerland+MC%2C+B%C3%BCchner+T%2C+Hiddemann+W&amp;rft.aulast=Haferlach+T%2C+Schoch+C%2C+L%C3%B6ffler+H%2C+Gassmann+W%2C+Kern+W%2C+Schnittger+S%2C+Fonatsch+C%2C+Ludwig+WD%2C+Wuchter+C%2C+Schlegelberger+B%2C+Staib+P%2C+Reichle+A%2C+Kubica+U%2C+Eimermacher+H%2C+Balleisen+L%2C+Gr%C3%BCneisen+A%2C+Haase+D%2C+Aul+C%2C+Karow+J%2C+Lengfelder+E%2C+W%C3%B6rmann+B%2C+Heinecke+A%2C+Sauerland+MC%2C+B%C3%BCchner+T%2C+Hiddemann+W&amp;rft.date=2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Ffull%2F21%2F2%2F256&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2003.08.005&amp;rft_id=info%3Apmid%2F12525517&amp;rft.issue=2&amp;rft.jtitle=J.+Clin.+Oncol.&amp;rft.pages=256-65&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=21" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-65"><span class="mw-cite-backlink"><b><a href="#cite_ref-65">^</a></b></span> <span class="reference-text"><span class="citation journal">Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Löffler H, Sauerland CM, Serve H, Büchner T, Haferlach T, Hiddemann W (2002). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/100/1/59">"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease"</a>. <i>Blood</i> <b>100</b> (1): 59–66. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood.V100.1.59">10.1182/blood.V100.1.59</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12070009">12070009</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Analysis+of+FLT3+length+mutations+in+1003+patients+with+acute+myeloid+leukemia%3A+correlation+to+cytogenetics%2C+FAB+subtype%2C+and+prognosis+in+the+AMLCG+study+and+usefulness+as+a+marker+for+the+detection+of+minimal+residual+disease&amp;rft.aulast=Schnittger+S%2C+Schoch+C%2C+Dugas+M%2C+Kern+W%2C+Staib+P%2C+Wuchter+C%2C+L%C3%B6ffler+H%2C+Sauerland+CM%2C+Serve+H%2C+B%C3%BCchner+T%2C+Haferlach+T%2C+Hiddemann+W&amp;rft.au=Schnittger+S%2C+Schoch+C%2C+Dugas+M%2C+Kern+W%2C+Staib+P%2C+Wuchter+C%2C+L%C3%B6ffler+H%2C+Sauerland+CM%2C+Serve+H%2C+B%C3%BCchner+T%2C+Haferlach+T%2C+Hiddemann+W&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F100%2F1%2F59&amp;rft_id=info%3Adoi%2F10.1182%2Fblood.V100.1.59&amp;rft_id=info%3Apmid%2F12070009&amp;rft.issue=1&amp;rft.jtitle=Blood&amp;rft.pages=59-66&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=100" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid17942876-66"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17942876_66-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Thornton KA, Levis M (2007). "Images in clinical medicine. FLT3 Mutation and acute myelogenous leukemia with leukostasis". <i>N. Engl. J. Med.</i> <b>357</b> (16): 1639. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJMicm064764">10.1056/NEJMicm064764</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17942876">17942876</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Images+in+clinical+medicine.+FLT3+Mutation+and+acute+myelogenous+leukemia+with+leukostasis&amp;rft.aulast=Thornton+KA%2C+Levis+M&amp;rft.au=Thornton+KA%2C+Levis+M&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMicm064764&amp;rft_id=info%3Apmid%2F17942876&amp;rft.issue=16&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=1639&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=357" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-67"><span class="mw-cite-backlink"><b><a href="#cite_ref-67">^</a></b></span> <span class="reference-text"><span class="citation journal">Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD (2006). <a rel="nofollow" class="external text" href="http://jco.ascopubs.org/cgi/content/full/24/24/3904">"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study"</a>. <i>J. Clin. Oncol.</i> <b>24</b> (24): 3904–11. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1200%2FJCO.2006.06.9500">10.1200/JCO.2006.06.9500</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16921041">16921041</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Adverse+prognostic+significance+of+KIT+mutations+in+adult+acute+myeloid+leukemia+with+inv%2816%29+and+t%288%3B21%29%3A+a+Cancer+and+Leukemia+Group+B+Study&amp;rft.aulast=Paschka+P%2C+Marcucci+G%2C+Ruppert+AS%2C+Mr%C3%B3zek+K%2C+Chen+H%2C+Kittles+RA%2C+Vukosavljevic+T%2C+Perrotti+D%2C+Vardiman+JW%2C+Carroll+AJ%2C+Kolitz+JE%2C+Larson+RA%2C+Bloomfield+CD&amp;rft.au=Paschka+P%2C+Marcucci+G%2C+Ruppert+AS%2C+Mr%C3%B3zek+K%2C+Chen+H%2C+Kittles+RA%2C+Vukosavljevic+T%2C+Perrotti+D%2C+Vardiman+JW%2C+Carroll+AJ%2C+Kolitz+JE%2C+Larson+RA%2C+Bloomfield+CD&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Ffull%2F24%2F24%2F3904&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2006.06.9500&amp;rft_id=info%3Apmid%2F16921041&amp;rft.issue=24&amp;rft.jtitle=J.+Clin.+Oncol.&amp;rft.pages=3904-11&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=24" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-68">^</a></b></span> <span class="reference-text"><span class="citation journal">Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH (1998). <a rel="nofollow" class="external text" href="http://content.nejm.org/cgi/content/full/339/23/1649">"Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission"</a>. <i>N. Engl. J. Med.</i> <b>339</b> (23): 1649–56. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJM199812033392301">10.1056/NEJM199812033392301</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9834301">9834301</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Chemotherapy+compared+with+autologous+or+allogeneic+bone+marrow+transplantation+in+the+management+of+acute+myeloid+leukemia+in+first+remission&amp;rft.au=Cassileth+PA%2C+Harrington+DP%2C+Appelbaum+FR%2C+Lazarus+HM%2C+Rowe+JM%2C+Paietta+E%2C+Willman+C%2C+Hurd+DD%2C+Bennett+JM%2C+Blume+KG%2C+Head+DR%2C+Wiernik+PH&amp;rft.aulast=Cassileth+PA%2C+Harrington+DP%2C+Appelbaum+FR%2C+Lazarus+HM%2C+Rowe+JM%2C+Paietta+E%2C+Willman+C%2C+Hurd+DD%2C+Bennett+JM%2C+Blume+KG%2C+Head+DR%2C+Wiernik+PH&amp;rft.date=1998&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fcontent.nejm.org%2Fcgi%2Fcontent%2Ffull%2F339%2F23%2F1649&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM199812033392301&amp;rft_id=info%3Apmid%2F9834301&amp;rft.issue=23&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=1649-56&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=339" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-69"><span class="mw-cite-backlink"><b><a href="#cite_ref-69">^</a></b></span> <span class="reference-text"><span class="citation journal">Matthews JP, Bishop JF, Young GA, Juneja SK, Lowenthal RM, Garson OM, Cobcroft RG, Dodds AJ, Enno A, Gillett EA, Hermann RP, Joshua DE, Ma DD, Szer J, Taylor KM, Wolf M, Bradstock KF (2001). "Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia". <i>Br. J. Haematol.</i> <b>113</b> (3): 727–36. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1046%2Fj.1365-2141.2001.02756.x">10.1046/j.1365-2141.2001.02756.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11380464">11380464</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Patterns+of+failure+with+increasing+intensification+of+induction+chemotherapy+for+acute+myeloid+leukaemia&amp;rft.aulast=Matthews+JP%2C+Bishop+JF%2C+Young+GA%2C+Juneja+SK%2C+Lowenthal+RM%2C+Garson+OM%2C+Cobcroft+RG%2C+Dodds+AJ%2C+Enno+A%2C+Gillett+EA%2C+Hermann+RP%2C+Joshua+DE%2C+Ma+DD%2C+Szer+J%2C+Taylor+KM%2C+Wolf+M%2C+Bradstock+KF&amp;rft.au=Matthews+JP%2C+Bishop+JF%2C+Young+GA%2C+Juneja+SK%2C+Lowenthal+RM%2C+Garson+OM%2C+Cobcroft+RG%2C+Dodds+AJ%2C+Enno+A%2C+Gillett+EA%2C+Hermann+RP%2C+Joshua+DE%2C+Ma+DD%2C+Szer+J%2C+Taylor+KM%2C+Wolf+M%2C+Bradstock+KF&amp;rft.date=2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1046%2Fj.1365-2141.2001.02756.x&amp;rft_id=info%3Apmid%2F11380464&amp;rft.issue=3&amp;rft.jtitle=Br.+J.+Haematol.&amp;rft.pages=727-36&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=113" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-70">^</a></b></span> <span class="reference-text"><span class="citation journal">Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, Díaz-Mediavilla J, Fioritoni G, González JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F (15 August 2000). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/96/4/1247">"Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups"</a>. <i>Blood</i> <b>96</b> (4): 1247–53. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10942364">10942364</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Definition+of+relapse+risk+and+role+of+nonanthracycline+drugs+for+consolidation+in+patients+with+acute+promyelocytic+leukemia%3A+a+joint+study+of+the+PETHEMA+and+GIMEMA+cooperative+groups&amp;rft.aulast=Sanz+MA%2C+Lo+Coco+F%2C+Mart%C3%ADn+G%2C+Avvisati+G%2C+Ray%C3%B3n+C%2C+Barbui+T%2C+D%C3%ADaz-Mediavilla+J%2C+Fioritoni+G%2C+Gonz%C3%A1lez+JD%2C+Liso+V%2C+Esteve+J%2C+Ferrara+F%2C+Bolufer+P%2C+Bernasconi+C%2C+Gonzalez+M%2C+Rodeghiero+F%2C+Colomer+D%2C+Petti+MC%2C+Ribera+JM%2C+Mandelli+F&amp;rft.au=Sanz+MA%2C+Lo+Coco+F%2C+Mart%C3%ADn+G%2C+Avvisati+G%2C+Ray%C3%B3n+C%2C+Barbui+T%2C+D%C3%ADaz-Mediavilla+J%2C+Fioritoni+G%2C+Gonz%C3%A1lez+JD%2C+Liso+V%2C+Esteve+J%2C+Ferrara+F%2C+Bolufer+P%2C+Bernasconi+C%2C+Gonzalez+M%2C+Rodeghiero+F%2C+Colomer+D%2C+Petti+MC%2C+Ribera+JM%2C+Mandelli+F&amp;rft.date=15+August+2000&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F96%2F4%2F1247&amp;rft_id=info%3Apmid%2F10942364&amp;rft.issue=4&amp;rft.jtitle=Blood&amp;rft.pages=1247-53&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=96" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-71"><span class="mw-cite-backlink"><b><a href="#cite_ref-71">^</a></b></span> <span class="reference-text"><span class="citation journal">Leone G, Mele L, Pulsoni A, Equitani F, Pagano L (1 October 1999). <a rel="nofollow" class="external text" href="http://www.haematologica.org/cgi/reprint/84/10/937">"The incidence of secondary leukemias"</a>. <i>Haematologica</i> <b>84</b> (10): 937–45. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10509043">10509043</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=The+incidence+of+secondary+leukemias&amp;rft.aulast=Leone+G%2C+Mele+L%2C+Pulsoni+A%2C+Equitani+F%2C+Pagano+L&amp;rft.au=Leone+G%2C+Mele+L%2C+Pulsoni+A%2C+Equitani+F%2C+Pagano+L&amp;rft.date=1+October+1999&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.haematologica.org%2Fcgi%2Freprint%2F84%2F10%2F937&amp;rft_id=info%3Apmid%2F10509043&amp;rft.issue=10&amp;rft.jtitle=Haematologica&amp;rft.pages=937-45&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=84" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-72"><span class="mw-cite-backlink"><b><a href="#cite_ref-72">^</a></b></span> <span class="reference-text"><span class="citation journal">Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001). "Cancer statistics, 2001". <i>CA Cancer J Clin</i> <b>51</b> (1): 15–36. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.3322%2Fcanjclin.51.1.15">10.3322/canjclin.51.1.15</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11577478">11577478</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Cancer+statistics%2C+2001&amp;rft.au=Greenlee+RT%2C+Hill-Harmon+MB%2C+Murray+T%2C+Thun+M&amp;rft.aulast=Greenlee+RT%2C+Hill-Harmon+MB%2C+Murray+T%2C+Thun+M&amp;rft.date=2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.3322%2Fcanjclin.51.1.15&amp;rft_id=info%3Apmid%2F11577478&amp;rft.issue=1&amp;rft.jtitle=CA+Cancer+J+Clin&amp;rft.pages=15-36&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=51" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-73"><span class="mw-cite-backlink"><b><a href="#cite_ref-73">^</a></b></span> <span class="reference-text"><span class="citation book">Linet MS (1985). "The leukemias: Epidemiologic aspects.". In Lilienfeld AM. <i>Monographs in Epidemiology and Biostatistics</i>. New York: Oxford University Press. p.&#160;I. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-19-503448-1" title="Special:BookSources/0-19-503448-1">0-19-503448-1</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=The+leukemias%3A+Epidemiologic+aspects.&amp;rft.aulast=Linet+MS&amp;rft.au=Linet+MS&amp;rft.btitle=Monographs+in+Epidemiology+and+Biostatistics&amp;rft.date=1985&amp;rft.genre=bookitem&amp;rft.isbn=0-19-503448-1&amp;rft.pages=I&amp;rft.place=New+York&amp;rft.pub=Oxford+University+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-74">^</a></b></span> <span class="reference-text"><span class="citation book">Aoki K; Kurihars M; Hayakawa N (1992). <i>Death Rates for Malignant Neoplasms for Selected Sites by Sex and Five-Year Age Group in 33 Countries 1953–57 to 1983–87</i>. Nagoya, Japan: University of Nagoya Press, International Union Against Cancer.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.au=Aoki+K&amp;rft.au=Hayakawa+N&amp;rft.au=Kurihars+M&amp;rft.aulast=Aoki+K&amp;rft.btitle=Death+Rates+for+Malignant+Neoplasms+for+Selected+Sites+by+Sex+and+Five-Year+Age+Group+in+33+Countries+1953%E2%80%9357+to+1983%E2%80%9387&amp;rft.date=1992&amp;rft.genre=book&amp;rft.place=Nagoya%2C+Japan&amp;rft.pub=University+of+Nagoya+Press%2C+International+Union+Against+Cancer&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-75"><span class="mw-cite-backlink"><b><a href="#cite_ref-75">^</a></b></span> <span class="reference-text"><span class="citation journal">Bhatia S, Neglia JP (1995). "Epidemiology of childhood acute myelogenous leukemia". <i>J. Pediatr. Hematol. Oncol.</i> <b>17</b> (2): 94–100. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2F00043426-199505000-00002">10.1097/00043426-199505000-00002</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7749772">7749772</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Epidemiology+of+childhood+acute+myelogenous+leukemia&amp;rft.au=Bhatia+S%2C+Neglia+JP&amp;rft.aulast=Bhatia+S%2C+Neglia+JP&amp;rft.date=1995&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2F00043426-199505000-00002&amp;rft_id=info%3Apmid%2F7749772&amp;rft.issue=2&amp;rft.jtitle=J.+Pediatr.+Hematol.+Oncol.&amp;rft.pages=94-100&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=17" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-76"><span class="mw-cite-backlink"><b><a href="#cite_ref-76">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/cancer-info/cancerstats/types/leukaemia-aml/">"Acute myeloid leukaemia (AML) statistics"</a>. <i>Cancer Research UK</i><span class="reference-accessdate">. Retrieved <span class="nowrap">27 October</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Acute+myeloid+leukaemia+%28AML%29+statistics&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fcancer-info%2Fcancerstats%2Ftypes%2Fleukaemia-aml%2F&amp;rft.jtitle=Cancer+Research+UK&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-77"><span class="mw-cite-backlink"><b><a href="#cite_ref-77">^</a></b></span> <span class="reference-text">Hoffman <i>et al.</i> 2005, pg 1071</span></li>
<li id="cite_note-78"><span class="mw-cite-backlink"><b><a href="#cite_ref-78">^</a></b></span> <span class="reference-text"><span class="citation journal">Bennett JH (1845). "Two cases of hypertrophy of the spleen and liver, in which death took place from suppuration of blood". <i>Edinburgh Med Surg J</i> <b>64</b>: 413.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Two+cases+of+hypertrophy+of+the+spleen+and+liver%2C+in+which+death+took+place+from+suppuration+of+blood&amp;rft.au=Bennett+JH&amp;rft.aulast=Bennett+JH&amp;rft.date=1845&amp;rft.genre=article&amp;rft.jtitle=Edinburgh+Med+Surg+J&amp;rft.pages=413&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=64" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-79"><span class="mw-cite-backlink"><b><a href="#cite_ref-79">^</a></b></span> <span class="reference-text"><span class="citation book">Virchow, R (1856). "Die Leukämie". In Virchow R. <i>Gesammelte Abhandlungen zur Wissenschaftlichen Medizin</i> (in German). Frankfurt: Meidinger. p.&#160;190.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Die+Leuk%C3%A4mie&amp;rft.aufirst=R&amp;rft.aulast=Virchow&amp;rft.au=Virchow%2C+R&amp;rft.btitle=Gesammelte+Abhandlungen+zur+Wissenschaftlichen+Medizin&amp;rft.date=1856&amp;rft.genre=bookitem&amp;rft.pages=190&amp;rft.place=Frankfurt&amp;rft.pub=Meidinger&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-80"><span class="mw-cite-backlink"><b><a href="#cite_ref-80">^</a></b></span> <span class="reference-text"><span class="citation journal">Ebstein W (1889). "Über die acute Leukämie und Pseudoleukämie". <i>Deutsch Arch Klin Med</i> <b>44</b>: 343.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=%C3%9Cber+die+acute+Leuk%C3%A4mie+und+Pseudoleuk%C3%A4mie&amp;rft.au=Ebstein+W&amp;rft.aulast=Ebstein+W&amp;rft.date=1889&amp;rft.genre=article&amp;rft.jtitle=Deutsch+Arch+Klin+Med&amp;rft.pages=343&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=44" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-81"><span class="mw-cite-backlink"><b><a href="#cite_ref-81">^</a></b></span> <span class="reference-text"><span class="citation journal">Mosler F (1876). "Klinische Symptome und Therapie der medullären Leukämie". <i>Berl Klin Wochenschr</i> <b>13</b>: 702.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Klinische+Symptome+und+Therapie+der+medull%C3%A4ren+Leuk%C3%A4mie&amp;rft.aulast=Mosler+F&amp;rft.au=Mosler+F&amp;rft.date=1876&amp;rft.genre=article&amp;rft.jtitle=Berl+Klin+Wochenschr&amp;rft.pages=702&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=13" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-82"><span class="mw-cite-backlink"><b><a href="#cite_ref-82">^</a></b></span> <span class="reference-text"><span class="citation journal">Naegeli O (1900). "Über rothes Knochenmark und Myeloblasten". <i>Deutsch Med Wochenschr</i> <b>26</b> (18): 287. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1055%2Fs-0029-1203820">10.1055/s-0029-1203820</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=%C3%9Cber+rothes+Knochenmark+und+Myeloblasten&amp;rft.aulast=Naegeli+O&amp;rft.au=Naegeli+O&amp;rft.date=1900&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1055%2Fs-0029-1203820&amp;rft.issue=18&amp;rft.jtitle=Deutsch+Med+Wochenschr&amp;rft.pages=287&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=26" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-83"><span class="mw-cite-backlink"><b><a href="#cite_ref-83">^</a></b></span> <span class="reference-text"><span class="citation journal">Wang ZY (2003). <a rel="nofollow" class="external text" href="http://asheducationbook.hematologylibrary.org/cgi/content/full/2003/1/1">"Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis"</a>. <i>Hematology</i> <b>2003</b> (1): 1–13. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fasheducation-2003.1.1">10.1182/asheducation-2003.1.1</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14633774">14633774</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=Ham-Wasserman+Lecture%3A+Treatment+of+Acute+Leukemia+by+Inducing+Differentiation+and+Apoptosis&amp;rft.aulast=Wang+ZY&amp;rft.au=Wang+ZY&amp;rft.date=2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fasheducationbook.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F2003%2F1%2F1&amp;rft_id=info%3Adoi%2F10.1182%2Fasheducation-2003.1.1&amp;rft_id=info%3Apmid%2F14633774&amp;rft.issue=1&amp;rft.jtitle=Hematology&amp;rft.pages=1-13&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=2003" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-84"><span class="mw-cite-backlink"><b><a href="#cite_ref-84">^</a></b></span> <span class="reference-text"><span class="citation journal">Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK (2008). <a rel="nofollow" class="external text" href="http://www.nature.com/nature/journal/v456/n7218/abs/nature07485.html">"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome"</a>. <i><a href="/wiki/Nature_(journal)" title="Nature (journal)">Nature</a></i> <b>456</b> (7218): 66–72. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnature07485">10.1038/nature07485</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2603574">2603574</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18987736">18987736</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=DNA+sequencing+of+a+cytogenetically+normal+acute+myeloid+leukaemia+genome&amp;rft.aulast=Ley+TJ%2C+Mardis+ER%2C+Ding+L%2C+Fulton+B%2C+McLellan+MD%2C+Chen+K%2C+Dooling+D%2C+Dunford-Shore+BH%2C+McGrath+S%2C+Hickenbotham+M%2C+Cook+L%2C+Abbott+R%2C+Larson+DE%2C+Koboldt+DC%2C+Pohl+C%2C+Smith+S%2C+Hawkins+A%2C+Abbott+S%2C+Locke+D%2C+Hillier+LW%2C+Miner+T%2C+Fulton+L%2C+Magrini+V%2C+Wylie+T%2C+Glasscock+J%2C+Conyers+J%2C+Sander+N%2C+Shi+X%2C+Osborne+JR%2C+Minx+P%2C+Gordon+D%2C+Chinwalla+A%2C+Zhao+Y%2C+Ries+RE%2C+Payton+JE%2C+Westervelt+P%2C+Tomasson+MH%2C+Watson+M%2C+Baty+J%2C+Ivanovich+J%2C+Heath+S%2C+Shannon+WD%2C+Nagarajan+R%2C+Walter+MJ%2C+Link+DC%2C+Graubert+TA%2C+DiPersio+JF%2C+Wilson+RK&amp;rft.au=Ley+TJ%2C+Mardis+ER%2C+Ding+L%2C+Fulton+B%2C+McLellan+MD%2C+Chen+K%2C+Dooling+D%2C+Dunford-Shore+BH%2C+McGrath+S%2C+Hickenbotham+M%2C+Cook+L%2C+Abbott+R%2C+Larson+DE%2C+Koboldt+DC%2C+Pohl+C%2C+Smith+S%2C+Hawkins+A%2C+Abbott+S%2C+Locke+D%2C+Hillier+LW%2C+Miner+T%2C+Fulton+L%2C+Magrini+V%2C+Wylie+T%2C+Glasscock+J%2C+Conyers+J%2C+Sander+N%2C+Shi+X%2C+Osborne+JR%2C+Minx+P%2C+Gordon+D%2C+Chinwalla+A%2C+Zhao+Y%2C+Ries+RE%2C+Payton+JE%2C+Westervelt+P%2C+Tomasson+MH%2C+Watson+M%2C+Baty+J%2C+Ivanovich+J%2C+Heath+S%2C+Shannon+WD%2C+Nagarajan+R%2C+Walter+MJ%2C+Link+DC%2C+Graubert+TA%2C+DiPersio+JF%2C+Wilson+RK&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fnature%2Fjournal%2Fv456%2Fn7218%2Fabs%2Fnature07485.html&amp;rft_id=info%3Adoi%2F10.1038%2Fnature07485&amp;rft_id=info%3Apmc%2F2603574&amp;rft_id=info%3Apmid%2F18987736&amp;rft.issue=7218&amp;rft.jtitle=Nature&amp;rft.pages=66-72&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=456" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Shapira-85"><span class="mw-cite-backlink">^ <a href="#cite_ref-Shapira_85-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Shapira_85-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Shapira T, Pereg D, Lishner M (September 2008). "How I treat acute and chronic leukemia in pregnancy". <i>Blood Rev.</i> <b>22</b> (5): 247–59. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.blre.2008.03.006">10.1016/j.blre.2008.03.006</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18472198">18472198</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAcute+myeloid+leukemia&amp;rft.atitle=How+I+treat+acute+and+chronic+leukemia+in+pregnancy&amp;rft.aulast=Shapira+T%2C+Pereg+D%2C+Lishner+M&amp;rft.au=Shapira+T%2C+Pereg+D%2C+Lishner+M&amp;rft.date=September+2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.blre.2008.03.006&amp;rft_id=info%3Apmid%2F18472198&amp;rft.issue=5&amp;rft.jtitle=Blood+Rev.&amp;rft.pages=247-59&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=22" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit&amp;section=28" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a rel="nofollow" class="external text" href="https://www.dmoz.org/Health/Conditions_and_Diseases/Cancer/Hematologic/Leukemia/Acute_Myelogenous/">Acute myeloid leukemia</a> at <a href="/wiki/DMOZ" title="DMOZ">DMOZ</a></li>
<li><a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=cebpa-aml">GeneReviews/NIH/NCBI/UW entry on Familial Acute Myeloid Leukemia (AML) with Mutated CEBPA</a></li>
<li><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancer_information/doc.aspx?viewid=4d3f920e-87d6-4b6a-a2fe-74c6efa53398&amp;version=1">PDQ statement on AML for health professionals</a> at <a href="/wiki/National_Cancer_Institute" title="National Cancer Institute">National Cancer Institute</a></li>
</ul>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Myeloid_malignancy" title="Template:Myeloid malignancy"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Myeloid_malignancy" title="Template talk:Myeloid malignancy"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Myeloid_malignancy&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%"><a href="/wiki/Myeloid" title="Myeloid">Myeloid</a> <a href="/wiki/Hematological_malignancy" title="Hematological malignancy" class="mw-redirect">hematological malignancy</a>/<a href="/wiki/Leukemia" title="Leukemia">leukemia</a> histology (<a href="/wiki/International_Classification_of_Diseases_for_Oncology" title="International Classification of Diseases for Oncology">ICD-O</a> 9590–9989, <a href="/wiki/ICD-10_Chapter_II:_Neoplasms#.28C81.E2.80.93C96.29_Malignant_neoplasms.2C_stated_or_presumed_to_be_primary.2C_of_lymphoid.2C_haematopoietic_and_related_tissue" title="ICD-10 Chapter II: Neoplasms">C81–C96</a>, <a href="/wiki/List_of_ICD-9_codes_140%E2%80%93239:_neoplasms#Malignant_neoplasm_of_lymphatic_and_hematopoietic_tissue_.28200.E2.80.93208.29" title="List of ICD-9 codes 140–239: neoplasms">200–208</a>)</div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-GM" title="CFU-GM">CFU-GM</a>/<br />
and other <a href="/wiki/Granulocyte" title="Granulocyte">granulocytes</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-GM" title="CFU-GM">CFU-GM</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Myelocyte" title="Myelocyte">Myelocyte</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><strong class="selflink">AML</strong>:</i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_myeloblastic_leukemia" title="Acute myeloblastic leukemia">Acute myeloblastic leukemia</a></li>
<li><a href="/wiki/Minimally_differentiated_acute_myeloblastic_leukemia" title="Minimally differentiated acute myeloblastic leukemia">M0</a></li>
<li><a href="/wiki/Acute_myeloblastic_leukemia_without_maturation" title="Acute myeloblastic leukemia without maturation">M1</a></li>
<li><a href="/wiki/Acute_myeloblastic_leukemia_with_maturation" title="Acute myeloblastic leukemia with maturation">M2</a></li>
<li><a href="/wiki/Acute_promyelocytic_leukemia" title="Acute promyelocytic leukemia">APL/M3</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">MP</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Chronic_neutrophilic_leukemia" title="Chronic neutrophilic leukemia">Chronic neutrophilic leukemia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Monocyte" title="Monocyte">Monocyte</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><strong class="selflink">AML</strong></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_monocytic_leukemia" title="Acute monocytic leukemia">AMoL/M5</a></li>
<li><a href="/wiki/Acute_myeloid_dendritic_cell_leukemia" title="Acute myeloid dendritic cell leukemia">Myeloid dendritic cell leukemia</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Chronic_myelogenous_leukemia" title="Chronic myelogenous leukemia">CML</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Philadelphia_chromosome" title="Philadelphia chromosome">Philadelphia chromosome</a></li>
<li><a href="/wiki/Accelerated_phase_chronic_myelogenous_leukemia" title="Accelerated phase chronic myelogenous leukemia">Accelerated phase chronic myelogenous leukemia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Myelomonocyte" title="Myelomonocyte">Myelomonocyte</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><strong class="selflink">AML</strong></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_myelomonocytic_leukemia" title="Acute myelomonocytic leukemia">M4</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myelodysplastic%E2%80%93myeloproliferative_diseases" title="Myelodysplastic–myeloproliferative diseases">MD-MP</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Juvenile_myelomonocytic_leukemia" title="Juvenile myelomonocytic leukemia">Juvenile myelomonocytic leukemia</a></li>
<li><a href="/wiki/Chronic_myelomonocytic_leukemia" title="Chronic myelomonocytic leukemia">Chronic myelomonocytic leukemia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Other</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Histiocytosis" title="Histiocytosis">Histiocytosis</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-Baso" title="CFU-Baso">CFU-Baso</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><strong class="selflink">AML</strong></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_basophilic_leukemia" title="Acute basophilic leukemia">Acute basophilic</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-Eos" title="CFU-Eos">CFU-Eos</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><strong class="selflink">AML</strong></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_eosinophilic_leukemia" title="Acute eosinophilic leukemia">Acute eosinophilic</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">MP</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Chronic_eosinophilic_leukemia" title="Chronic eosinophilic leukemia">Chronic eosinophilic leukemia</a>/<a href="/wiki/Hypereosinophilic_syndrome" title="Hypereosinophilic syndrome">Hypereosinophilic syndrome</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Megakaryocyte%E2%80%93erythroid_progenitor_cell" title="Megakaryocyte–erythroid progenitor cell">MEP</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-Meg" title="CFU-Meg">CFU-Meg</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><strong class="selflink">AML</strong></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_megakaryoblastic_leukemia" title="Acute megakaryoblastic leukemia">AMKL/M7</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">MP</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Essential_thrombocytosis" title="Essential thrombocytosis" class="mw-redirect">Essential thrombocytosis</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-E" title="CFU-E">CFU-E</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><strong class="selflink">AML</strong></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_erythroid_leukemia" title="Acute erythroid leukemia">Erythroleukemia/M6</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">MP</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Polycythemia_vera" title="Polycythemia vera">Polycythemia vera</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myelodysplastic_syndrome" title="Myelodysplastic syndrome">MD</a></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Anemia" title="Anemia">Refractory anemia</a></li>
<li><a href="/wiki/Refractory_anemia_with_excess_of_blasts" title="Refractory anemia with excess of blasts">Refractory anemia with excess of blasts</a></li>
<li><a href="/wiki/Chromosome_5q_deletion_syndrome" title="Chromosome 5q deletion syndrome">Chromosome 5q deletion syndrome</a></li>
<li><a href="/wiki/Sideroblastic_anemia" title="Sideroblastic anemia">Sideroblastic anemia</a></li>
<li><a href="/wiki/Paroxysmal_nocturnal_hemoglobinuria" title="Paroxysmal nocturnal hemoglobinuria">Paroxysmal nocturnal hemoglobinuria</a></li>
<li><a href="/wiki/Refractory_cytopenia_with_multilineage_dysplasia" title="Refractory cytopenia with multilineage dysplasia">Refractory cytopenia with multilineage dysplasia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-Mast" title="CFU-Mast">CFU-Mast</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Mastocytoma" title="Mastocytoma">Mastocytoma</a></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Mast_cell_leukemia" title="Mast cell leukemia">Mast cell leukemia</a></li>
<li><a href="/wiki/Mast_cell_sarcoma" title="Mast cell sarcoma">Mast cell sarcoma</a></li>
<li><a href="/wiki/Mastocytosis" title="Mastocytosis">Systemic mastocytosis</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><a href="/wiki/Mastocytosis" title="Mastocytosis">Mastocytosis</a>:</span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Diffuse_cutaneous_mastocytosis" title="Diffuse cutaneous mastocytosis">Diffuse cutaneous mastocytosis</a></li>
<li><a href="/wiki/Erythrodermic_mastocytosis" title="Erythrodermic mastocytosis">Erythrodermic mastocytosis</a></li>
<li><a href="/wiki/Adult_type_of_generalized_eruption_of_cutaneous_mastocytosis" title="Adult type of generalized eruption of cutaneous mastocytosis">Adult type of generalized eruption of cutaneous mastocytosis</a></li>
<li><a href="/wiki/Urticaria_pigmentosa" title="Urticaria pigmentosa">Urticaria pigmentosa</a></li>
<li><a href="/wiki/Mast_cell_sarcoma" title="Mast cell sarcoma">Mast cell sarcoma</a></li>
<li><a href="/wiki/Solitary_mastocytoma" title="Solitary mastocytoma">Solitary mastocytoma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;">Systemic mastocytosis</span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Xanthelasmoidal_mastocytosis" title="Xanthelasmoidal mastocytosis">Xanthelasmoidal mastocytosis</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Multiple/unknown</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><strong class="selflink">AML</strong></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_panmyelosis_with_myelofibrosis" title="Acute panmyelosis with myelofibrosis">Acute panmyelosis with myelofibrosis</a></li>
<li><a href="/wiki/Myeloid_sarcoma" title="Myeloid sarcoma">Myeloid sarcoma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">MP</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Myelofibrosis" title="Myelofibrosis">Myelofibrosis</a></li>
<li><a href="/wiki/Acute_biphenotypic_leukaemia" title="Acute biphenotypic leukaemia">Acute biphenotypic leukaemia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;">
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Myeloid_navs" title="Template:Myeloid navs"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Myeloid_navs" title="Template talk:Myeloid navs"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Myeloid_navs&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%">Index of <a href="/wiki/Myeloid" title="Myeloid">cells from bone marrow</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Description</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Myeloid_innate_immune_system" title="Template:Myeloid innate immune system">Immune system</a></li>
<li><a href="/wiki/Template:Myeloid_blood_cells_and_plasma" title="Template:Myeloid blood cells and plasma">Cells</a></li>
<li><a href="/wiki/Template:Myeloid_physiology" title="Template:Myeloid physiology">Physiology</a>
<ul>
<li><a href="/wiki/Template:Coagulation" title="Template:Coagulation">coagulation</a></li>
<li><a href="/wiki/Template:Hemeproteins" title="Template:Hemeproteins">proteins</a></li>
<li><a href="/wiki/Template:Granule_contents" title="Template:Granule contents">granule contents</a></li>
<li><a href="/wiki/Template:Colony-stimulating_factors" title="Template:Colony-stimulating factors">colony-stimulating</a></li>
<li>heme and porphyrin
<ul>
<li><i><a href="/wiki/Template:Porphyrin_metabolism_enzymes" title="Template:Porphyrin metabolism enzymes">metabolism</a></i></li>
<li><i><a href="/wiki/Template:Heme_metabolism_intermediates" title="Template:Heme metabolism intermediates">intermediates</a></i></li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Disease</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Diseases_of_RBCs_and_megakaryocytes" title="Template:Diseases of RBCs and megakaryocytes">Red blood cell</a></li>
<li><a href="/wiki/Template:Monocyte_and_granulocyte_disease" title="Template:Monocyte and granulocyte disease">Monocyte and granulocyte</a></li>
<li><a href="/wiki/Template:Myeloid_malignancy" title="Template:Myeloid malignancy">Neoplasms and cancer</a></li>
<li><a href="/wiki/Template:Histiocytosis" title="Template:Histiocytosis">Histiocytosis</a></li>
<li><a href="/wiki/Template:Cardiovascular_system_symptoms_and_signs" title="Template:Cardiovascular system symptoms and signs">Symptoms and signs</a>
<ul>
<li><a href="/wiki/Template:Eponymous_medical_signs_for_hematology" title="Template:Eponymous medical signs for hematology">eponymous</a></li>
</ul>
</li>
<li><a href="/wiki/Template:Myeloid_blood_tests" title="Template:Myeloid blood tests">Blood tests</a>
<ul>
<li><a href="/wiki/Template:Abnormal_clinical_and_laboratory_findings_for_blood" title="Template:Abnormal clinical and laboratory findings for blood">findings</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Treatment</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Transfusion_medicine" title="Template:Transfusion medicine">Transfusion</a></li>
<li>Drugs
<ul>
<li><a href="/wiki/Template:Antithrombotics" title="Template:Antithrombotics">thrombosis</a></li>
<li><a href="/wiki/Template:Antihemorrhagics" title="Template:Antihemorrhagics">bleeding</a></li>
<li><a href="/wiki/Template:B03,_B05,_B06" title="Template:B03, B05, B06">other</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Parsed by mw1242
CPU time usage: 0.705 seconds
Real time usage: 0.810 seconds
Preprocessor visited node count: 5325/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 289085/2097152 bytes
Template argument size: 1582/2097152 bytes
Highest expansion depth: 12/40
Expensive parser function count: 1/500
Lua time usage: 0.274/10.000 seconds
Lua memory usage: 3.42 MB/50 MB
-->

<!-- 
Transclusion expansion time report (%,ms,calls,template)
100.00%  649.067      1 - -total
 55.95%  363.149      1 - Template:Reflist
 32.81%  212.976     66 - Template:Cite_journal
 24.07%  156.225     14 - Template:Navbox
 13.60%   88.248      1 - Template:Myeloid_malignancy
  9.09%   58.983      1 - Template:Infobox_disease
  7.85%   50.940      1 - Template:Infobox
  6.16%   40.012      1 - Template:Featured_article
  5.89%   38.258      1 - Template:Top_icon
  4.71%   30.585      1 - Template:Use_dmy_dates
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:4323952-0!*!0!!en!4!* and timestamp 20150712000128 and revision id 666154792
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Acute_myeloid_leukemia&amp;oldid=666154792">https://en.wikipedia.org/w/index.php?title=Acute_myeloid_leukemia&amp;oldid=666154792</a>"					</div>
				<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Acute_myeloid_leukemia" title="Category:Acute myeloid leukemia">Acute myeloid leukemia</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:CS1_German-language_sources_(de)" title="Category:CS1 German-language sources (de)">CS1 German-language sources (de)</a></li><li><a href="/wiki/Category:Use_dmy_dates_from_March_2014" title="Category:Use dmy dates from March 2014">Use dmy dates from March 2014</a></li><li><a href="/wiki/Category:Articles_with_contributors_link" title="Category:Articles with contributors link">Articles with contributors link</a></li><li><a href="/wiki/Category:Articles_with_DMOZ_links" title="Category:Articles with DMOZ links">Articles with DMOZ links</a></li><li><a href="/wiki/Category:Articles_that_use_a_Medicine_navs_subtemplate" title="Category:Articles that use a Medicine navs subtemplate">Articles that use a Medicine navs subtemplate</a></li><li><a href="/wiki/Category:Featured_articles" title="Category:Featured articles">Featured articles</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>

			<div id="mw-head">
									<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-createaccount"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Acute+myeloid+leukemia&amp;type=signup" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Acute+myeloid+leukemia" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
															<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Acute_myeloid_leukemia"  title="View the content page [c]" accesskey="c">Article</a></span></li>
															<li  id="ca-talk"><span><a href="/wiki/Talk:Acute_myeloid_leukemia"  title="Discussion about the content page [t]" accesskey="t" rel="discussion">Talk</a></span></li>
													</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<h3 id="p-variants-label">
							<span>Variants</span><a href="#"></a>
						</h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
															<li id="ca-view" class="selected"><span><a href="/wiki/Acute_myeloid_leukemia" >Read</a></span></li>
															<li id="ca-edit"><span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=edit"  title="Edit this page [e]" accesskey="e">Edit</a></span></li>
															<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=history"  title="Past versions of this page [h]" accesskey="h">View history</a></span></li>
													</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<h3 id="p-cactions-label"><span>More</span><a href="#"></a></h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>

						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
							<input type="search" name="search" placeholder="Search" title="Search Wikipedia [f]" accesskey="f" id="searchInput" /><input type="hidden" value="Special:Search" name="title" /><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton" /><input type="submit" name="go" value="Go" title="Go to a page with this exact name if one exists" id="searchButton" class="searchButton" />							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
			<h3 id='p-navigation-label'>Navigation</h3>

			<div class="body">
									<ul>
						<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikimedia Shop">Wikipedia store</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
			<h3 id='p-interaction-label'>Interaction</h3>

			<div class="body">
									<ul>
						<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
			<h3 id='p-tb-label'>Tools</h3>

			<div class="body">
									<ul>
						<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Acute_myeloid_leukemia" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Acute_myeloid_leukemia" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;oldid=666154792" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="//www.wikidata.org/wiki/Q264118" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Acute_myeloid_leukemia&amp;id=666154792" title="Information on how to cite this page">Cite this page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
			<h3 id='p-coll-print_export-label'>Print/export</h3>

			<div class="body">
									<ul>
						<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Acute+myeloid+leukemia">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Acute+myeloid+leukemia&amp;oldid=666154792&amp;writer=rdf2latex">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Acute_myeloid_leukemia&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
			<h3 id='p-lang-label'>Languages</h3>

			<div class="body">
									<ul>
						<li class="interlanguage-link interwiki-ar"><a href="//ar.wikipedia.org/wiki/%D8%A7%D8%A8%D9%8A%D8%B6%D8%A7%D8%B6_%D8%A7%D9%84%D8%AF%D9%85_%D8%A7%D9%84%D9%86%D9%82%D9%88%D9%8A_%D8%A7%D9%84%D8%AD%D8%A7%D8%AF" title="ابيضاض الدم النقوي الحاد – Arabic" lang="ar" hreflang="ar">العربية</a></li><li class="interlanguage-link interwiki-ca"><a href="//ca.wikipedia.org/wiki/Leuc%C3%A8mia_aguda_mieloide" title="Leucèmia aguda mieloide – Catalan" lang="ca" hreflang="ca">Català</a></li><li class="interlanguage-link interwiki-de"><a href="//de.wikipedia.org/wiki/Akute_myeloische_Leuk%C3%A4mie" title="Akute myeloische Leukämie – German" lang="de" hreflang="de">Deutsch</a></li><li class="interlanguage-link interwiki-el"><a href="//el.wikipedia.org/wiki/%CE%9F%CE%BE%CE%B5%CE%AF%CE%B1_%CE%BC%CF%85%CE%B5%CE%BB%CE%BF%CE%B3%CE%B5%CE%BD%CE%AE%CF%82_%CE%BB%CE%B5%CF%85%CF%87%CE%B1%CE%B9%CE%BC%CE%AF%CE%B1" title="Οξεία μυελογενής λευχαιμία – Greek" lang="el" hreflang="el">Ελληνικά</a></li><li class="interlanguage-link interwiki-es badge-Q17437796 badge-featuredarticle" title="featured article"><a href="//es.wikipedia.org/wiki/Leucemia_mieloide_aguda" title="Leucemia mieloide aguda – Spanish" lang="es" hreflang="es">Español</a></li><li class="interlanguage-link interwiki-fa"><a href="//fa.wikipedia.org/wiki/%D9%84%D9%88%D8%B3%D9%85%DB%8C_%D8%AD%D8%A7%D8%AF_%D9%85%DB%8C%D9%84%D9%88%D8%A6%DB%8C%D8%AF%DB%8C" title="لوسمی حاد میلوئیدی – Persian" lang="fa" hreflang="fa">فارسی</a></li><li class="interlanguage-link interwiki-fr"><a href="//fr.wikipedia.org/wiki/Leuc%C3%A9mie_aigu%C3%AB_my%C3%A9loblastique" title="Leucémie aiguë myéloblastique – French" lang="fr" hreflang="fr">Français</a></li><li class="interlanguage-link interwiki-ko"><a href="//ko.wikipedia.org/wiki/%EA%B8%89%EC%84%B1_%EA%B3%A8%EC%88%98%EC%84%B1_%EB%B0%B1%ED%98%88%EB%B3%91" title="급성 골수성 백혈병 – Korean" lang="ko" hreflang="ko">한국어</a></li><li class="interlanguage-link interwiki-hr"><a href="//hr.wikipedia.org/wiki/Akutna_mijeloi%C4%8Dna_leukemija" title="Akutna mijeloična leukemija – Croatian" lang="hr" hreflang="hr">Hrvatski</a></li><li class="interlanguage-link interwiki-it"><a href="//it.wikipedia.org/wiki/Leucemia_mieloide_acuta" title="Leucemia mieloide acuta – Italian" lang="it" hreflang="it">Italiano</a></li><li class="interlanguage-link interwiki-he"><a href="//he.wikipedia.org/wiki/%D7%9C%D7%95%D7%A7%D7%9E%D7%99%D7%94_%D7%9E%D7%99%D7%90%D7%9C%D7%95%D7%90%D7%99%D7%93%D7%99%D7%AA_%D7%97%D7%A8%D7%99%D7%A4%D7%94" title="לוקמיה מיאלואידית חריפה – Hebrew" lang="he" hreflang="he">עברית</a></li><li class="interlanguage-link interwiki-lt"><a href="//lt.wikipedia.org/wiki/%C5%AAmin%C4%97_mielogenin%C4%97_leukemija" title="Ūminė mielogeninė leukemija – Lithuanian" lang="lt" hreflang="lt">Lietuvių</a></li><li class="interlanguage-link interwiki-hu"><a href="//hu.wikipedia.org/wiki/Akut_mieloid_leuk%C3%A9mia" title="Akut mieloid leukémia – Hungarian" lang="hu" hreflang="hu">Magyar</a></li><li class="interlanguage-link interwiki-nl"><a href="//nl.wikipedia.org/wiki/Acute_myelo%C3%AFde_leukemie" title="Acute myeloïde leukemie – Dutch" lang="nl" hreflang="nl">Nederlands</a></li><li class="interlanguage-link interwiki-new"><a href="//new.wikipedia.org/wiki/%E0%A4%8F%E0%A4%95%E0%A5%8D%E0%A4%AF%E0%A5%81%E0%A4%9F_%E0%A4%AE%E0%A4%BE%E0%A4%AF%E0%A4%B2%E0%A5%8B%E0%A4%87%E0%A4%A1_%E0%A4%B2%E0%A5%8D%E0%A4%AF%E0%A5%81%E0%A4%95%E0%A5%87%E0%A4%AE%E0%A4%BF%E0%A4%AF%E0%A4%BE" title="एक्युट मायलोइड ल्युकेमिया – Newari" lang="new" hreflang="new">नेपाल भाषा</a></li><li class="interlanguage-link interwiki-ja"><a href="//ja.wikipedia.org/wiki/%E6%80%A5%E6%80%A7%E9%AA%A8%E9%AB%84%E6%80%A7%E7%99%BD%E8%A1%80%E7%97%85" title="急性骨髄性白血病 – Japanese" lang="ja" hreflang="ja">日本語</a></li><li class="interlanguage-link interwiki-ps"><a href="//ps.wikipedia.org/wiki/%D8%AD%D8%A7%D8%AF_%D9%85%D8%A7%D9%8A%D9%84%D9%88%D9%8A%D9%8A%D8%AF_%D9%84%D9%8A%D9%88%DA%A9%DB%90%D9%85%D9%8A" title="حاد مايلوييد ليوکېمي – Pashto" lang="ps" hreflang="ps">پښتو</a></li><li class="interlanguage-link interwiki-pl badge-Q17437796 badge-featuredarticle" title="featured article"><a href="//pl.wikipedia.org/wiki/Ostra_bia%C5%82aczka_szpikowa" title="Ostra białaczka szpikowa – Polish" lang="pl" hreflang="pl">Polski</a></li><li class="interlanguage-link interwiki-pt badge-Q17437796 badge-featuredarticle" title="featured article"><a href="//pt.wikipedia.org/wiki/Leucemia_mieloide_aguda" title="Leucemia mieloide aguda – Portuguese" lang="pt" hreflang="pt">Português</a></li><li class="interlanguage-link interwiki-ru"><a href="//ru.wikipedia.org/wiki/%D0%9E%D1%81%D1%82%D1%80%D1%8B%D0%B9_%D0%BC%D0%B8%D0%B5%D0%BB%D0%BE%D0%B8%D0%B4%D0%BD%D1%8B%D0%B9_%D0%BB%D0%B5%D0%B9%D0%BA%D0%BE%D0%B7" title="Острый миелоидный лейкоз – Russian" lang="ru" hreflang="ru">Русский</a></li><li class="interlanguage-link interwiki-sr"><a href="//sr.wikipedia.org/wiki/%D0%90%D0%BA%D1%83%D1%82%D0%BD%D0%B0_%D0%BC%D0%B8%D1%98%D0%B5%D0%BB%D0%BE%D1%86%D0%B8%D1%82%D0%BD%D0%B0_%D0%BB%D0%B5%D1%83%D0%BA%D0%B5%D0%BC%D0%B8%D1%98%D0%B0" title="Акутна мијелоцитна леукемија – Serbian" lang="sr" hreflang="sr">Српски / srpski</a></li><li class="interlanguage-link interwiki-sh"><a href="//sh.wikipedia.org/wiki/Akutna_mijelocitna_leukemija" title="Akutna mijelocitna leukemija – Serbo-Croatian" lang="sh" hreflang="sh">Srpskohrvatski / српскохрватски</a></li><li class="interlanguage-link interwiki-fi"><a href="//fi.wikipedia.org/wiki/Akuutti_myelooinen_leukemia" title="Akuutti myelooinen leukemia – Finnish" lang="fi" hreflang="fi">Suomi</a></li><li class="interlanguage-link interwiki-sv"><a href="//sv.wikipedia.org/wiki/Akut_myeloisk_leukemi" title="Akut myeloisk leukemi – Swedish" lang="sv" hreflang="sv">Svenska</a></li><li class="interlanguage-link interwiki-te"><a href="//te.wikipedia.org/wiki/%E0%B0%85%E0%B0%95%E0%B1%8D%E0%B0%AF%E0%B1%82%E0%B0%9F%E0%B1%8D_%E0%B0%AE%E0%B1%88%E0%B0%B2%E0%B0%BE%E0%B0%AF%E0%B0%A1%E0%B1%8D_%E0%B0%B2%E0%B1%81%E0%B0%95%E0%B1%87%E0%B0%AE%E0%B0%BF%E0%B0%AF%E0%B0%BE" title="అక్యూట్ మైలాయడ్ లుకేమియా – Telugu" lang="te" hreflang="te">తెలుగు</a></li><li class="interlanguage-link interwiki-th"><a href="//th.wikipedia.org/wiki/%E0%B8%A1%E0%B8%B0%E0%B9%80%E0%B8%A3%E0%B9%87%E0%B8%87%E0%B9%80%E0%B8%A1%E0%B9%87%E0%B8%94%E0%B9%80%E0%B8%A5%E0%B8%B7%E0%B8%AD%E0%B8%94%E0%B8%82%E0%B8%B2%E0%B8%A7%E0%B9%80%E0%B8%89%E0%B8%B5%E0%B8%A2%E0%B8%9A%E0%B8%9E%E0%B8%A5%E0%B8%B1%E0%B8%99%E0%B8%8A%E0%B8%99%E0%B8%B4%E0%B8%94%E0%B9%84%E0%B8%A1%E0%B8%AD%E0%B8%B4%E0%B8%A5%E0%B8%AD%E0%B8%A2%E0%B8%94%E0%B9%8C" title="มะเร็งเม็ดเลือดขาวเฉียบพลันชนิดไมอิลอยด์ – Thai" lang="th" hreflang="th">ไทย</a></li><li class="interlanguage-link interwiki-vi"><a href="//vi.wikipedia.org/wiki/B%E1%BB%87nh_b%E1%BA%A1ch_c%E1%BA%A7u_myeloid_c%E1%BA%A5p_t%C3%ADnh" title="Bệnh bạch cầu myeloid cấp tính – Vietnamese" lang="vi" hreflang="vi">Tiếng Việt</a></li><li class="interlanguage-link interwiki-zh"><a href="//zh.wikipedia.org/wiki/%E6%80%A5%E6%80%A7%E9%AA%A8%E9%AB%93%E6%80%A7%E7%99%BD%E8%A1%80%E7%97%85" title="急性骨髓性白血病 – Chinese" lang="zh" hreflang="zh">中文</a></li><li class="uls-p-lang-dummy"><a href="#"></a></li>					</ul>
				<div class='after-portlet after-portlet-lang'><span class="wb-langlinks-edit wb-langlinks-link"><a href="//www.wikidata.org/wiki/Q264118#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 9 June 2015, at 07:54.</li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="//wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Acute_myeloid_leukemia&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
											<li id="footer-copyrightico">
							<a href="//wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>						</li>
											<li id="footer-poweredbyico">
							<a href="//www.mediawiki.org/"><img src="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_132x47.png 1.5x, //en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" /></a>						</li>
									</ul>
						<div style="clear:both"></div>
		</div>
		<script>if(window.jQuery)jQuery.ready();</script><script>if(window.mw){
mw.loader.state({"ext.globalCssJs.site":"ready","ext.globalCssJs.user":"ready","site":"loading","user":"ready","user.groups":"ready"});
}</script>
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.cite.styles%7Cext.gadget.DRN-wizard%2CReferenceTooltips%2CWatchlistGreenIndicators%2Ccharinsert%2Cfeatured-articles-links%2CrefToolbar%2Cswitcher%2Cteahouse%7Cext.wikimediaBadges&amp;only=styles&amp;skin=vector&amp;*" />
<script>if(window.mw){
mw.loader.load(["ext.cite.a11y","mediawiki.toc","mediawiki.action.view.postEdit","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.searchSuggest","ext.cirrusSearch.loggingSchema","mmv.bootstrap.autostart","ext.imageMetrics.loader","ext.eventLogging.subscriber","ext.wikimediaEvents","ext.wikimediaEvents.statsd","ext.navigationTiming","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.WatchlistGreenIndicators","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.switcher","ext.gadget.featured-articles-links","ext.visualEditor.targetLoader","schema.UniversalLanguageSelector","ext.uls.eventlogger","ext.uls.interlanguage"],null,true);
}</script>
<script>if(window.mw){
document.write("\u003Cscript src=\"//en.wikipedia.org/w/load.php?debug=false\u0026amp;lang=en\u0026amp;modules=site\u0026amp;only=scripts\u0026amp;skin=vector\u0026amp;*\"\u003E\u003C/script\u003E");
}</script>
<script>if(window.mw){
mw.config.set({"wgBackendResponseTime":104,"wgHostname":"mw1256"});
}</script>
	</body>
</html>
